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SUMMARY 
 
In recent years, the research interests in glaucoma therapy have been shifted 
toward “ocular neuroprotection” because dropping the intraocular pressure has been 
shown to be unable to prevent progressive vision loss in glaucoma. Among several 
ocular neuroprotective approaches, induction of heat shock proteins (HSPs), 
particularly HSPs 72, in retinal ganglion cells (RGCs) has been paid considerable 
attention as an efficacious approach for ocular neuroprotection. However, the current 
biotechnical approaches to induced HSPs have critical limits to use in clinics due to 
undesirable systemic or chemical side effects and correspondingly low local induction 
efficiency of HSPs. 
 In this thesis, magnetic fluid hyperthermia (MFH) using a fluidic 
superparamagnetic nanoparticles (SPNPs) agent has been designed and explored as a 
potential modality to achieve the high efficient local induction of HSPs in RGCs and 
to minimize the cell death rate (side effects) by controlling AC heating stress in RGCs 
during HSPs induction process. 
Firstly, magnetic and AC magnetically-induced heating properties of Fe3O4 
nanoparticles, widely studied as a hyperthermia agent, were investigated and it was 
demonstrated that pure superparamagnetic phase Fe3O4 nanoparticles showed 
insufficient specific loss power (SLP) critically limiting for MFH applications. 
Accordingly, in order to develop a new powerful SPNP agent, we empirically and 
physically investigated the physical mechanisms of AC magnetically-induced heating 
and identified what physical parameters would be the most critical to enhance the AC 
magnetically-induced heating characteristics of SPNPs using various kinds of solid 
state SPNPs (Fe3O4, NiFe2O4, MgFe2O4, and MnxZn1-xFe2O4).  
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Secondly, the AC magnetically-induced heating characteristics of various viscous 
(1 × 10
-3
 Pa·s ~ 4 × 10-3 Pa·s) ferrofluids with either soft-ferrite or hard-ferrite SPNPs 
were investigated and analyzed to empirically interpret the contribution of Néel 
relaxation loss (soft-ferrite) or Brown relaxation loss (hard-ferrite) to the total AC heat 
generation of superparamagnetic MFH agents. The contribution of Brown relaxation 
loss was severely affected by the viscosity, while the contribution of Néel relaxation 
loss was independent of the variation of viscosity. 
Thirdly, the MnxZn1-xFe2O4 SPNPs were intensively explored as a potential 
candidate for a MFH agent. The effects of relative concentrations of Mn
2+
 cations and 
Zn
2+
 cations on the AC magnetically-induced heating characteristics, magnetic 
properties, and biocompatibilities of MnxZn1-xFe2O4 SPNPs were systematically 
investigated and it was found that the Mn0.5Zn0.5Fe2O4 SPNP showed the highest AC 
magnetically-induced heating temperature (TAC,mag), specific loss power (SLP), as 
well as biocompatibility.  
Fourthly, the Mn
2+
 cation concentration and its distribution in tetrahedral (A) and 
octahedral (B)-sites of the Mn0.5Zn0.5Fe2O4 SPNP were thermally controlled during a 
process of synthesizing nanoparticles to improve the magnetic properties and the AC 
magnetically-induced heating characteristics (engineered Mn0.5Zn0.5Fe2O4 SPNP, 
EMZF SPNP) for successful control of the AC heating stress in RGCs. In addition, 
applicability of EMZF SPNP to a MFH agent for local induction of HSPs 72 was 
demonstrated. 
Finally, the AC heating stress (or AC heating) controllable MFH was 
demonstrated to be promising for high efficient local induction of HSPs 72 in RGCs. 
The AC heating stress (AC heating) in RGCs was successfully controlled by tuning 
the applied AC magnetic field in the biologically tolerable and physiologically safe 
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). It was found that the induction efficiency of 
HSPs 72 and cell survival rate were significantly improved by controlling the AC 

















LIST OF TABLES 
 IX 
LIST OF TABLES 
Table 2-1 Various forces acting in a ferrofluids 28 
Table 4-1 Mean hydrodynamic diameters (dH), size distributions, and 









Table 4-3 Summaries of calculated and measured physical values 
(parameters) of Fe3O4 nanoparticles with different: AC/DC 
hysteresis area (loss), out-of-phase magnetic susceptibility, 





Table 5-1 Calculation results of the real contributions of PNeel relaxation loss 





Table 7-1 The effective concentration of EMZF@PEG SPNPs uptake in 
the RGCs quantitatively analyzed using an ICP-MS. The 
RGCs were treated and incubated by EMZF@PEG ferrofluids 


















LIST OF FIGURES 
 X 
LIST OF FIGURES 
 
Figure 2-1 Progressive loss of vision caused by glaucoma 12 
Figure 2-2 Damage of optic nerve or RGCs caused by increased IOP 
(left) and open angle glaucoma and closed angle glaucoma 




Figure 2-3 Created new channel for more normal flow of aqueous 
humor by trabeculectomy 
 
14 
Figure 2-4 The SOLX deep light glaucoma treatment system combines 
a titanium sapphire laser with a gold shunt (shown at far left 
next to a quarter and at right inserted into an eye). At lower 
left and right are photos of a patient’s trabecular meshwork 






Figure 2-5 Schematic diagram of induction of HSPs 17 
Figure 2-6 Schematic diagram of whole body hyperthermia to induce 
HSPs (left) and fundus photographs after laser irradiation 
with different powers (right): at high powers (> 120 mW), 









Figure 2-8 (a) Superficial microwave hyperthermia of malignant 
melanoma of the skin, (b) interstitial hyperthermia in a 




Figure 2-9 An example of (a) thermal chamber and (b) hot water 
blanket for whole-body hyperthermia 
 
22 
Figure 2-10 Experimental set-up for AC heat measurements of ferrofluids 23 
Figure 2-11 Formation of colloidal suspension 25 
Figure 2-12 Schematic diagram of the property of SPNPs fluid 27 
Figure 2-13 Kinds of magnetism 30 
Figure 2-14 Hysteresis loops of (left) single-domain (smaller particle) 
and multi-domain (larger particle) and (right) 




Figure 2-15 Effect of particle size on the magnetic coercivity 32 




Figure 2-17 Relaxation time vs particle size for magnetite particles 35 
Figure 2-18 Relaxation times of magnetic moment orientational 
dynamics as a function of particle diameter and viscosity 
 
35 




Figure 3-1 Illustration of HTTD method for synthesis of SPNPs  46 
Figure 3-2 Procedure of HTTD method to synthesize SPNPs 48 
Figure 3-3 TEM images of silica and PEG coated MnxZn1-xFe2O4 
SPNPs (coating thickness: ~ 2 mn) and ferrofluids with PEG, 




LIST OF FIGURES 
 XI 
Figure 3-4 Schematic diagram of structure of TEM 51 
Figure 3-5 LS 7407 VSM system 52 
Figure 3-6 Bragg diffraction. Two incident waves with identical 
wavelength and phase approach a crystalline solid ant are 
scattered off two different atoms within it. The lower beam 
traverses an extra length of 2dsinƟ. Constructive 
interference occurs when this length is equal to an integer 







Figure 3-7 XRD patterns for all the nanoparticles used in this thesis 54 
Figure 3-8 Physical property measurement system, Quantum Design 55 
Figure 3-9 AC magnetic field generation system 57 
Figure 3-10 Structure of DLS, Zetasizer Nano ZS 58 
Figure 4-1 TEM images of Fe3O4 nanoparticles with different mean 
diameters. (a) 4.2 nm, (b) 5.8 nm, (c) 9.8 nm, (d) 11.8 nm, 




Figure 4-2 (a) Dependence of saturation magnetization and coercivity 
on the particle size of Fe3O4 nanoparticles, and (b) ZFC/FC 






Figure 4-3 AC magnetically-induced heating characteristics of Fe3O4 
nanoparticles with different particle sizes measured at Happl 
of 140 Oe and fappl of 110 kHz: (a) solid state Fe3O4 
nanoparticles and (b) DMSA coated Fe3O4 nanoparticles 






Figure 4-4 Minor hysteresis loops of Fe3O4 nanoparticles: (a) DC minor 
hysteresis loops swept at Happl of ±140 Oe, and (b) AC 
minor hysteresis loops swept at the fixed fappl of 110 kHz 





Figure 5-1 The particle size and the size distributions of the 
superparamagnetic MgFe2O4, NiFe2O4 and Mn0.5Zn0.5Fe2O4 




Figure 5-2 DC minor hysteresis loop of superparamagnetic 
nanoparticles measured at a DC Happl of ±140 Oe 
 
84 
Figure 5-3 AC magnetically-induced heating temperatures of solid state 
superparamagnetic nanoparticles measured at the fixed Happl 




Figure 5-4 Intrinsic magnetic properties of all the three 
superparamagnetic nanoparticles: (a) AC hysteresis loop, (b) 
AC hysteresis loop measured at the sweeping field of ± 25 
Oe with fappl: 110 kHz, (c) in-phase magnetic susceptibility, 






Figure 5-5 Studies of in-vitro biocompatibility of the superparamagnetic 
nanoparticles: (a) cell survival rate of all the 
superparamagnetic nanoparticles with neuronal stem cells, 
and (b) TEM study results of cellular uptake characteristics 








Figure 5-6 The mean particle size and size distribution of synthesized  
LIST OF FIGURES 
 XII 




Figure 5-7 The DC minor hysteresis loop of (a) CoFe2O4 and (b) Fe3O4 





Figure 5-8 The hydrodynamic diameter (dH), the Z-potential, and the 
poly dispersity index (PDI) of silica coated (a) CoFe2O4 and 




Figure 5-9 TEM study results of retinal ganglion cells (RGCs) before 
and after treating by ferrofluids: (a) control RGCs, (b) RGCs 
treated by silica coated CoFe2O4 SPNPs ferrofluid, and (c) 





Figure 5-10 (a) The inductance-capacitance (L-C) controlled AC 
magnetically-induced heating system used for measuring AC 
heating of Co- and Fe-ferrofluids with different viscosities. 
Figure (b), and (c) show the dependence of surrounding 
viscosity of Co-ferrofluid, and Fe-ferrofluid on the AC 
magnetically-induced heating temperature rise 
characteristics. The viscosity of two ferrofluids was varied 
from 1 × 10
-3











Figure 5-11 The dependence of viscosity on the (a) specific loss power, 
and (b) total AC heating power in AC magnetically-induced 




Figure 6-1 TEM images and XRD patterns of synthesized 
superparamagnetic MnxZn1-xFe2O4 nanoparticles with 
different Mn composition: (a) x = 0.33, (b) x = 0.5, (c) x = 





Figure 6-2 5-2 Minor magnetic hysteresis loops of MnxZn1-xFe2O4 
SPNPs with different Mn-Zn concentration changed from x 




Figure 6-3 (a) Major magnetic hysteresis loops and (b) Ms values of 
MnxZn1-xFe2O4 SPNPs with different Mn-Zn concentration 
changed from x = 0.2 to x = 0.8, and (c) Magnetic spin 





Figure 6-4 (a) Dependence of Mn
2+
 concentration on the AC 
magnetically-induced heating temperature measured at the 
fixed Happl = 80 Oe and fappl = 210 kHz, and Dependence of 
applied (b) magnetic field and (c) frequency on the AC 








Figure 6-5 Measured (a) out-of-phase magnetic susceptibilities and (b) 
AC magnetic hysteresis loops of MnxZn1-xFe2O4 SPNPs 
 
115 
Figure 6-6 Néel relaxation loss power, total heat generation power, and 
SLP (measured in solid state) of MnxZn1-xFe2O4 SPNPs 
 
117 
Figure 6-7 Cell viability of (a) MnxZn1-xFe2O4 SPNPs (x = 0.33, 0.5, 
and 0.67) with neuronal stem cells isolated from human fetal 
midbrain, and (b) Mn0.5Zn0.5Fe2O4 and Fe3O4 SPNPs with 





LIST OF FIGURES 
 XIII 
Figure 7-1 The specially designed AC magnetically-induced heating 





Figure 7-2 TEM images of uncoated engineered Mn0.5Zn0.5Fe2O4 
nanoparticles 
126 
Figure 7-3 (a) Measured ZFC/FC of EMZF-SPNPs at the applied field 
of 100 Oe, and (b) minor hysteresis loops of uncoated 
EMZF, conventional Mn0.5Zn0.5Fe2O4, and Fe3O4 SPNPs 





Figure 7-4 AC magnetically-induced heating temperature of the SPNPs 
measured in solid state 
 
128 
Figure 7-5 Intrinsic magnetic properties of EMZF, Mn0.5Zn0.5Fe2O4, and 





Figure 7-6 (a) HR-TEM image of EMZF@PEG SPNPs dispersed in 
water (the EMZF SPNP successfully coated with a very thin 
PEG layer around 2 nm thickness and they were well 
dispersed in water with minimal aggregation) and (b) FTIR 






Figure 7-7 DLS data including hydrodynamic diameter (dH), poly 
dispersity Index (PDI) and Z-potential for three nanofluids: 
(a) EMZF@PEG nanofluid, (b) conventional 







Figure 7-8 AC magnetically-induced heating temperature rise 
characteristics of three coated SPNPs dispersed in water 
measured at the fixed AC magnetic field of fappl = 140 kHz 
and Happl = 140 Oe with varied concentration of 1 mg/mL ~ 5 
mg/mL. (a) EMZF@PEG ferrofluid, (b) conventional 









Figure 7-9 The specific loss power (SLP) of all the ferrofluids 
calculated based on the AC heating characteristics obtained 




Figure 7-10 Studies of in-vitro biocompatibility of uncoated Fe3O4 and 
EMZF SPNPs and silica coated EMZF SPNPs with RGCs: 
(a) Cell survival rate of uncoated EMZF and Fe3O4 and silica 
coated (thickness: 2 nm ~ 7 nm) EMZF SPNPs with different 
nanoparticle concentrations, and (b) TEM study results of 









Figure 7-11 Studies of in-vitro biocompatibility of EMZF@PEG and 
Fe3O4@PEG SPNPs with RGCs: (a) Cell survival rate of 
EMZF@PEG and Fe3O4@PEG SPNPs with different 
concentrations, and (b) TEM study results of RGCs treated 






Figure 7-12 AC magnetically-induced heating temperature rise 
characteristics of RGCs treated by EMZF@PEG SPNPs 
 
 
LIST OF FIGURES 
 XIV 
measured at the fixed applied frequency of 140 kHz and 
magnetic field of 140 Oe with the concentrations varied from 




Figure 7-13 The stained results of HSPs 72 induction (left), nucleus 
(middle), and HSPs 72 + nucleus (right) in the RGCs after 
MFH using EMZF@PEG SPNPs with the concentration 





Figure 7-14 AC magnetically-induced heating temperatures of RGCs 
treated by the EMZF@PEG SPNPs (500 μg/mL) with 
different holding time of AC heating from 600 sec to 1200 sec 
measured at the fixed applied frequency of 140 kHz and 






Figure 7-15 The stained results of HSPs 72 induction (left), nucleus 
(middle), and HSPs 72 + nucleus (right) in the RGCs after 
MFH using EMZF@PEG SPNPs controlled the holding time 





Figure 7-16 Western blot finding of HSPs 72 and β -actin (loading 
control). (a) RGCs only, (b) RGCs + AC magnetic field (fappl 
= 140 kHz, Happl = 140 Oe for 900 sec) + no EMZF@PEG 
SPNPs, (c) RGCs + EMZF@PEG SPNPs (500 μg/mL) + no 
AC magnetic field, and (d) RGCs + EMZF@PEG SPNPs 
(500 μg/mL) + AC magnetic field (fappl = 140 kHz, Happl = 
140 Oe for 900 sec ). The protein levels of HSPs 72 were 
assessed by Western blotting, which identified the induction 











Figure 7-17 (a) AC magnetically-induced heating temperature rise 
behaviors of RGCs pellets treated by 500 µg/mL of 
EMZF@PEG and Fe3O4@PEG SPNPs measured at the fixed 
AC magnetic field of fappl = 140 kHz and Happl = 140 Oe, and 
(b) the stained results of HSPs 72 induction in the RGCs after 







Figure 7-18 Dependence of increasing rate of AC heating stress or AC 
heating-up rate, (ΔT/Δt) to a constant HSPs temperature of 
40.5 ℃ ± 0.5 ℃ on the local induction rate of HSPs 72 and 
the cell survival rate (or cell death rate) in RGCs treated by 
500 µg/mL of EMZF@PEG ferrofluidic solution.: (a) control 
group, RGCs with EMZF@PEG SPNPs but no applied AC 
magnetic field, (b) ΔT/Δt = 0.118 ℃/s, fappl= 140 kHz, Happl = 
160 Oe, (c) ΔT/Δt = 0.091 ℃/s, fappl= 140 kHz, Happl = 140 
Oe, (d) ΔT/Δt = 0.062 ℃/s, fappl= 140 kHz, Happl = 130 Oe, 















Figure 7-20 Duty cycle controlled AC heating temperatures (AC heating) 
of RGCs treated by EMZF@PEG SPNPs.: (a) D: 25 %, (b) D: 




Figure 7-21 The dependence of HSPs 72 induction and the cell death rate  
LIST OF FIGURES 
 XV 
on the controlling duty cycle of the AC heaing.: (a) D: 25 %, 
(b) D: 50 %, (c) D: 75 %, and (d) D: 100 % 
 
153 
Figure 7-22 The calculation results of (a) cell death rate and HSPs 72 
induction rate and (b) HSPs 72 induction efficiency by 




Figure 7-23 A new infusion technique to introduce SPNPs to the surface of 
retina layer and the histological exam results to investigate the 
distribution status of the injected SPNPs and cell apoptosis: (a) 
Injection of uncoated and silica coated EMZF SPNPs into the 
rat eyeball and (b) Diffusion of the EMZF SPNPs thorough the 
vitreous body, (c) Control retina paraffin block, (d) 
Histological exam results of the retina paraffin block exposed 
to the uncoated EMZF SPNPs and (e) The EMZF 
SPNPs@silica, and (f) The enlarged inner plexiform layer of 











   
PUBLICATIONS AND CONFERENCES 
 XVI 
PUBLICATIONS AND CONFERENCES 
Journal Publications: 
 
Minhong Jeun, Yu Jeong Kim, Ki Ho Park, Sun Ha Paek, and Seongtae Bae, 
“Physical contribution of Néel and Brown relaxation to interpreting intracellular 
hyperthermia characteristics using superparamagnetic nanofluids” J. Nanosci. & 
Nanotech., in-press (2013) 
 
Minhong Jeun, Sanghoon Lee, Yu Jeong Kim, Hwa-Yeon Jo, Ki Ho Park, Sun Ha 
Paek, Yasushi Takemura,and Seongtae Bae, “Physical Parameters to Enhance AC 
Magnetically-Induced Heating Power of Magnetic Nanoparticles for Hyperthermia in 
Nanomedicine” IEEE Transactions on Nanotechnology, in-press (2013) 
 
Minhong Jeun, Sanghoon Lee, Jae Kyeong Kang, Asahi Tomitaka, Keon Wook 
Kang, Young Il Kim, Yasushi Takemura, Kyung-Won Chung, Jiyeon Kwak, and 
Seongtae Bae, “Physical Limits of Pure Superparamagnetic Fe3O4 Nanoparticles for a 
Local Hyperthermia Agent in Nanomedicine” Appl. Phys. Lett. 100, 092406 (2012) 
 
Minhong Jeun, Jin Wook Jeong, Seung Je Moon, Yu Jeong Kim, Sanghoon Lee, Sun 
Ha Paek, Kyung-Won Chung, Ki Ho Park, and Seongtae Bae, “Engineered 
Superparamagnetic Mn0.5Zn0.5Fe2O4 Nanoparticles as a Heat Shock Protein Induction 
Agent for Ocular Neuroprotection in Glaucoma” Biomaterials 32, 387 (2011) 
 
PUBLICATIONS AND CONFERENCES 
 XVII 
Minhong Jeun, Seung Je Moon, Hiroki Kobayashi, Hye Young Shin, Asahi 
Tomitaka, Yu Jeong Kim, Yasushi Takemura, Sun Ha Paek, Ki Ho Park, Kyung-Won 
Chung, and Seongtae Bae, “Effects of Mn Concentration on the AC 
Magnetically-Induced Heating Characteristics of Superparamagnetic MnxZn1-xFe2O4 
Nanoparticles for Hyperthermia” Appl. Phys. Lett. 96, 202511 (2010) 
 
Minhong Jeun, Seongtae Bae, Asahi Tomitaka, Yasushi Takemura, Ki Ho Park, Sun 
Ha Paek, and Kyung-Won Chung, “Effects of Particle Dipole Interaction on the AC 
Magnetically-Induced Heating Characteristics of Ferrite Nanoparticles for 
Hyperthermia” Appl. Phys. Lett. 95, 082501 (2009) 
 
Minhong Jeun, Lin Lin, Ho Wan Joo, Seongtae Bae, Jang Heo and Ky Am Lee, 
“"Villari Reversal" in the Exchange Biased [Pd/Co]5/FeMn Thin Films with 
Perpendicular Anisotropy” Appl. Phys. Lett. 94, 152512 (2009) 
 
Asahi Tomitaka, Minhong Jeun, Seongtae Bae, and Yasushi Takemura, “Evaluation 
of Magnetic and Thermal Properties of Ferrite Nanoparticles for Biomedical 
Applications” Journal of Magnetics 16(2), 164 (2011) 
 
Asahi Tomitaka, Hiroki Kobayashi, Tsutomu Yamada, Minhong Jeun, Seongtae Bae 
and Yasushi Takemura, “Magnetic Characterization and Self-heating of Various 
Magnetic Nanoparticles for Medical Applications” IEEE Nanoelectronics 
conference 10, 896 (2010) 
 
Hiroki Kobayashi, Atsuo Hirukawa, Asahi Tomitaka, Tsutomu Yamada, Minhong 
Jeun, Seongtae Bae and Yasushi Takemura, “Self-Heating Properties under AC 
PUBLICATIONS AND CONFERENCES 
 XVIII 
Magnetic Field and Their Evaluation by AC/DC Hysteresis Loops of NiFe2O4 
Nanoparticles” J. Appl. Phys. 107, 09B322 (2010) 
 
Asahi Tomitaka, Hiroki Kobayashi, Tsutomu Yamada, Minhong Jeun, Seongtae Bae, 
and Yasushi Takemura, “Magnetization and Self-Heating Temperature of NiFe2O4 
Measured by Applying AC Magnetic Field” Journal of Physics 200, 122010 (2010) 
 
Conferences: 
Minhong Jeun, Sanghoon Lee, Jae Kyeong Kang, Yu Jeong Kim, Ki Ho Park, Sun 
Ha Paek, Yasushi Takemura, Young Il Kim, Keon Wook Kang, Kyung-Won Chung, 
Jiyeon Kwak, and Seongtae Bae, “Physical Evaluation of Néel and Brown Relaxation 
for Interpreting Intracellular Heating Mechanism of Superparamagnetic Fluid 
Hyperthermia in Nanomedicine” Intermag 2012, IEEE International Magnetics 
Conference, Vancuver, Canada (2012, 5, 7 ~ 11) 
 
Sanghoon Lee, Minhong Jeun, Jae kyeong Kang, Young Il Kim, Kyung-Won Chung, 
Jihyeon Kwak and Seongtae Bae, “Magnetically Engineered MgFe2O4 Nanoparticles 
Controlled by Calcining Process during Sol-Gel Synthesis for Intra-Arterial 
Hyperthermia” Intermag 2012, IEEE International Magnetics Conference, 
Vancuver, Canada (2012, 5, 7 ~ 11) 
 
Minhong Jeun, Sanghoon Lee, Hyunrim Oh, Yu Jeong Kim, Ki Ho Park, Sun Ha 
Paek, Yasushi Takemura, Kyung-Won Chung, Jiyeon Kwak, and Seongtae Bae, 
“Physical Parameters to Enhance AC Heating Characteristics of Superpara- and 
Ferri-Magnetic Nanoparticles for Local Hyperthermia” 56th MMM International 
Conference, Scottsdale, Arizona, USA (2011, 10, 30 ~ 11, 03) 
 
PUBLICATIONS AND CONFERENCES 
 XIX 
Minhong Jeun, Sanghoon Lee, Hyunrim Oh, Ashahi Tomitaka, Yasushi Takemura, 
Kyung-Won Chung, Young Il Kim, Keon Wook Kang, Jiyeon Kwak, and Seongtae 
Bae, “Physical Limits of Pure Superparamagnetic Fe3O4 Nanoparticles for a Local 
Hyperthermia Agent in Nanomedicine” 56th MMM International Conference, 
Scottsdale, Arizona, USA (2011, 10, 30 ~ 11, 03) 
 
Koji Ueda, Hiroki Kobayashi, Shinsuke Hatsugai, Asahi Tomitaka, Tsutomu, Yamada, 
Minhong Jeun, Seongtae Bae and Yasushi Takemura, “Evaluation of Magnetic 
Properties Measured by AC/DC Hysteresis Loops of Magnetic Nanoparticles for 
Hyperthermia Application” International Conference of the Asian Union of 
Magnetics Societies (ICAUMS), Jeju, Korea, (2010, 12, 8) 
 
Minhong Jeun, Jin Wook Jeong, Seung Je Moon, Yu Jeong Kim, Hye Young Shin, 
Sang Hoon Lee, Sun Ha Paek, Kyung-Won Chung, Ki Ho Park, and Seongtae Bae, 
“Feasibility of Engineered Superparamagnetic Mn0.5Zn0.5Fe2O4 Nanoparticles to a 
Localized Heat Shock Protein Agent for Ocular Neuroprotection in Glaucoma” 55th 
MMM International Conference, Atlanta, GA, USA (2010, 11, 14 ~ 18) 
 
Koji Ueda, Hiroki Kobayashi, Shinsuke Hatsugai, Asahi Tomitaka, Tsutomu Yamada, 
Minhong Jeun, Seongtae Bae, and Yasushi Takemura, “Self-Heating Evaluation and 
Magnetic Property of Different Size Magnetic Nanoparticles” 2nd ISAMMA, Sendai, 
Japan, (2010, 07) 
 
Asahi Tomitaka, Hiroki Kobayashi, Tsutomu Yamada, Minhong Jeun, Seongtae Bae 
and Yasushi Takemura, “Magnetic Characterization and Self-Heating of Various 
Magnetic Nanoparticles for Medical Applications” The 3rd IEEE International 
NanoElectronics Conference (INEC), Hong Kong, (2010, 01) 
 
Hiroki Kobayashi, Atsuo Hirukawa, Asahi Tomitaka, Tsutomu Yamada, Minhong 
Jeun, Seongtae Bae and Yasushi Takemura, “Self-Heating Properties under AC 
Magnetic Field and Their Evaluation by AC/DC Hysteresis Loops of NiFe2O4 
Nanoparticles” 11th Joint MMM-Intermag Conference, Washington, DC, USA (2010, 
1, 18 ~ 22) 
PUBLICATIONS AND CONFERENCES 
 XX 
 
Seung Je Moon, Minhong Jeun, Yan Ru Tan, Koji Ueda, Asahi Tomitaka, Yu Jeong 
Kim, Hye Young Shin, Yasushi Takemura, Ki Ho Park, Sun Ha Paek, Kyung-Won 
Chung, and Seongtae Bae, “Magnetic Properties, Biocompatibility, and AC 
Magnetically-Induced Heating Characteristics of Superparamagnetic NixZn1-xFe2O4 
Nanoparticles for Bioapplications” 11th Joint MMM-Intermag Conference, 
Washington, DC, USA (2010, 1, 18 ~ 22) 
 
Minhong Jeun, Lin lin, Ho Wan Joo, Seongtae Bae, Jang Heo, and Ky Am Lee, 
“Villari Reversal in the Exchange Biased [Pd/Co]5/FeMn Multilayered Thin Films 
with Perpendicular Anisotropy” 11th Joint MMM-Intermag Conference, Washington, 
DC, USA (2010, 1, 18 ~ 22) 
 
Minhong Jeun, Seungje Moon, Seongtae Bae, Sawlani Haresh Kalyan, Hiroki 
Kobayashi, Asahi Tomitaka, Yasushi Takemura, Yu Jeong Kim, Ki Ho Park, Sun Ha 
Paek, and Kyung-Won Chung, “AC Magnetically Induced Heating Characteristics 
and Bio-Compatibility of MnxZn1-xFe2O4 Superparamagnetic Nanoparticles for 
Hyperthermia Applications” 11th Joint MMM-Intermag Conference, Washington, 
DC, USA (2010, 1, 18 ~ 22) 
 
Asahi Tomitaka, Hiroki Kobayashi, Tsutomu Yamada, Minhong Jeun, Seongtae Bae, 
Yasushi Takemura, “Magnetization and Self-Heating Temperature of NiFe2O4 
Measured by Applying AC Magnetic Field” International Conference on Magnetism 
(ICM), Karlsruhe, Germany (2009, 7 26 ~ 31) 
 
Sang Won Lee, Seongtae Bae, Minhong Jeun, Tomohiro Koshi, and Yasushi 
Takemura, “AC Magnetically Induced Heating of Solid State Superparamagnetic 
Ferrite Nanoparticles and Its Physical Characteristics for Hyperthermia” 53rd MMM 
Conference, Austin, Texas, USA (2008. 11. 10 ~ 14) 
 
 
LIST OF ABBREVIATIONS AND SYMBOLS 
 XXI 
LIST OF ABBREVIATIONS AND SYMBOLS 
AC   alternating current 
ARVO  Association for Research in Vision and Ophthalmology 
CCK  cell counting kit 
CHPP  continuous hyperthermic peritoneal perfusion 
CNS  central nervous system 
DC   direct current 
DLS  dynamic light scattering system 
DMEM  Dulbecco’s modified eagle medium 
F3Lacz  human neural cells 
fappl   applied ac frequency 
Happl  applied magnetic field 
HSPs  heat shock proteins 
HTTD  high temperature thermal decomposition 
IOP   increase of intraocular pressure 
MFH  magnetic fluid hyperthermia 
MPMS  magnetic property measurement system 
NSC  neuronal stem cells 
PBS  phosphate buttered saline 
PBST  phosphate buttered saline tween-20 
PDI   polydispersity index 
PEG  polyethylene glycol  
PPMS  physical property measurement system 
RGCs  retinal ganglion cells 
LIST OF ABBREVIATIONS AND SYMBOLS 
 XXII 
RT   room temperature 
SLP  specific loss power 
SPNPs  superparamagnetic nanoparticles 
TAC,mag  AC magnetically-induced heating temperature 
TB   blocking temperature 
TEM  transmission of electron microscope 
Tmax  maximum temperature 
TTT  transpupillary thermotherapy  
VSM  vibrating sample magnetometer 
XRD  X-ray diffraction 
ZFC/FC    Zero field cooling/field cooling 
A         AC hysteresis loop (area) 












CHAPTER 1 INTRODUCTION 
 1 
CHAPTER 1 INTRODUCTION 
1.1 Background and Motivation 
 Neurodegeneration has been considered as a main cause for different types of 
neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease, 
dementia, and stroke [1,2]. According to the previous reports, the progressive loss of 
function or programmed death (apoptosis) of neurons in the central nervous system 
(CNS) was revealed to primarily result in causing the neurodegeneration. Hence, the 
protection of neurons against programmed death or continuous damage (or loss), so 
called "neuroprotection", by different biotechnical approaches, such as direct 
introduction of genes, induction of heat shock protein, injection of stem cells, and 
drugs, has been paid considerable attentions for effectively treating the 
neurodegenerative diseases [2-6]. 
 Among the various eye diseases, glaucoma is considered as a well known 
neurodegenerative disease. It is a progressive and incurable optic neuropathy where 
the optic nerve is damaged with the loss of retinal ganglion cells (RGCs) due to 
mechanical injuries. This disease has been considered as one of the most fatal diseases 
responsible for irreversible blindness [7,8]. Ocular hypertension, the increase of 
intraocular pressure (IOP), is a typical symptom and has been widely accepted for the 
main risk factor to cause the damage of optic nerve and RGCs [7-9]. Accordingly, all 
of the treatment modalities for glaucoma so far were entirely focused on dropping the 
IOP such as by taking a medicine or by doing surgical operation [10,11]. However, 
since these treatment methods have been found to temporarily cure glaucoma and not 
to be effective for protecting ocular neurons, “ocular neuroprotection”, the interest to 
apply previously developed "neuroprotection" modalities to the prevention of RGCs 
from glaucoma-induced progressive loss (death) have been rapidly increased in 
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glaucoma clinics [12-14]. Correspondingly, various neuroprotective drug (or 
inhibitor)-based modalities have attempted to prevent the damaged RGCs from the 
progressive loss or death, but although they were proven to reduce the death of 
damaged RGCs [12], high toxicity and the unclear mechanism for protecting RGCs of 
some drugs were revealed to be critical limitations for clinical use [1,14]. Thus, 
alternatively, the local induction of heat shock proteins (HSPs) has been recently 
considered to be a more effective and safer modality for ocular neuroprotection in 
glaucoma [15-16].  
 The HSPs can be induced in living cells by hyperthermia, metabolic stress, or 
oxygen deprivation [17,18]. In particular, HSPs 70 or 72 families in the mammalian 
central nervous system (CNS) has been known to enhance neuronal tolerance against 
ischemic insults and confirmed to be effective for ocular neuroprotection against 
light-induced injuries in a rat retina [16,19,20,21]. Since then, several experimental 
approaches such as Zn injection, whole body hyperthermia, and thermotherapy using 
laser etc. have been introduced and attempted to induce HSPs 72 for 
ocular-neuroprotection. However, although the research efforts made so far 
successfully demonstrated to identify the induction of HSPs 72 in RGCs, these 
biotechnical approaches caused the systemic or chemical side effects [22-24]. 
Moreover, some of critical issues relevant to real clinical applications: 1) how the 
HSPs 72 can be locally induced at targeted sites, 2) how the induction efficiency of 
local HSPs 72 can be accurately controlled and significantly enhanced, and 3) how the 
death rate of healthy cells (caused by applied stress) can be minimized during the 
induction of HSPs 72 process in RGCs, have been raised to be solved for developing 
much physiologically and biologically safer as well as more effective local induction 
of HSPs modality. Therefore, to settle down these current biotechnical challenges, the 
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development of new biotechnical or biomedical engineering approach enabling to 
achieve high efficient local induction of HSPs 72 in RGCs is inevitably required for 
ocular neuroprotection in modern glaucoma clinics. 
 In view of these biomedical or biotechnical requirements, magnetic fluid 
hyperthermia (MFH) using superparamagnetic nanoparticles (SPNPs, diameter (d): < 
10 nm) agents can be considered to be a new promising biomedical approach to 
induce local HSPs 72. The main reason is that it can allow to locally generate the 
thermal stress ("AC magnetically-induced heat stress" or "AC heating stress") in 
RGCs during the induction of HSPs. Particularly, another crucial reason is that the 
"AC heating stress", which is directly relevant to the biochemical behavior of HSPs as 
well as the HSPs efficiency, can be controlled by tuning the AC magnetically-induced 
heating characteristics of MFH agents by controlling the externally applied AC 
magnetic field. The systematically controllable "AC heating stress" during HSPs 
induction process is expected to be able to enhance the efficiency of HSPs induction, 
i.e. high induction rate of HSPs and minimal death rate of healthy cells, because the 
change of thermal stress in cells including RGCs directly influences on the cytological 
behaviors such as induction of HSPs and cell apoptosis [24-28]. 
 For the successful demonstration of high efficient local induction of HSPs 72 in 
RGCs by "AC heating stress" controllable MFH, the most crucial issue to be satisfied 
is to develop a high performance SPNPs MFH agent. The SPNPs considered for 
inducing HSPs 72 in RGCs needs several specific biotechnical requirements that it 
should: 1) exhibit a high biocompatibility including a high cell viability with RGCs 
and a high cellular uptake efficiency by the RGCs, 2) generate the AC 
magnetically-induced heating temperature (TAC,mag) as high as possible at a small 
concentration (a higher specific loss power, SLP) in the biological safe and 
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) [29], 3) be successfully injected to the surface of retina (or RGCs) using a 
newly developed infusion technique, because the currently considered injection 
technique, which intravenously infuse the SPNP agents through the veins in an in-vivo 
MFH modality, cannot be applied to an eye. However, unfortunately, considering 
these specific requirements of MFH agent for ocular neuroprotection, the Fe3O4 
SPNPs, which are currently used for both clinical MFH and MRI agents due to the 
officially approved biocompatibility [30], are not suitable because of a insufficient 
SLP at a low fappl and a small Happl, chemical instability, and a relatively large particle 
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1.2 Research Objectives 
 The main objective of this thesis is the development and application of MFH 
using a high performance SPNP agent as a new promising modality for effective and 
physiologically & biologically safe local induction of HSPs 72 for ocular 
neuroprotection. This project implementation is divided into more specific objectives 
in order to realize the main aim of the thesis: 
 
A. Improvement of magnetic properties and AC magnetically-induced heating 
(AC heating) characteristics, and study on physical mechanisms to design a 
promising SPNP agent 
a. Synthesis of SPNPs (d < 10 nm) by using a conventional and a modified 
high temperature thermal decomposition (HTTD) method 
b. Setting up of the AC magnetic field generation system for investigating 
the AC heating characteristics and MFH (intracellular studies) 
c. Analysis of structure, AC/DC magnetic properties, and AC heating 
characteristics of SPNPs in both solid state and fluid state 
d. Investigation of the physical contribution of Néel and Brown relaxation 
loss power to the AC heating power of fluidic SPNPs 
e. Understand the physical mechanisms of the AC heating and the crucial 
physical parameters to improve the AC heating power and SLP 
f. Confirmation of biocompatibility 
 
B. Development and characterization of MnxZn1-xFe2O4 SPNPs for MFH agent 
applications to induce local HSPs 72 
a. Optimization of a modified HTTD method for synthesizing 
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MnxZn1-xFe2O4 SPNPs 
b. Investigation of the effect of Mn2+ concentrations on the biocompatibilities, 
magnetic properties and AC heating characteristics 
c. Determination of the optimized composition of the MnxZn1-xFe2O4 SPNPs 
for MFH agent applications 
d. Confirmation of cell viability and cellular uptake efficiency 
 
C. Local induction of HSPs 72 in RGCs using MFH and improvement of HSP 72 
induction efficiency 
a. Measurement of the AC heating temperature in RGCs treated by SPNPs 
b. Control of the AC heating stress in RGCs by systematically tuning the AC 
heating characteristics of SPNPs to improve the efficiency of HSPs 72 
induction 
c. Identification of the induction of HSPs 72 
d. Investigation of the correlation between the change of AC heating stress 
and the behavior of HSPs 72 induction 
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1.3 Organization of Thesis 
 Chapter 1 presents the background, motivations, and objectives of this thesis. 
Chapter 2 reviews the previous works relevant to this project and discusses the 
theoretical background on the magnetic properties and the AC magnetically-induced 
heating of magnetic nanoparticles. A summary of current research trends in 
hyperthermia and MFH will be also presented. Chapter 3 presents the synthesis 
methods of SPNPs and biocompatible materials coating techniques to form a 
ferrofluid for MFH agent applications. In addition, the various characterization 
techniques and in-vitro & in–vivo experimental methods are introduced. In chapter 4, 
physical limits of superparamagnetic Fe3O4 nanoparticles which have been the most 
commonly studied material for MFH agent applications are discussed. In chapter 5, 
physical studies for improving the AC magnetically-induced heating characteristics of 
SPNPs are discussed. Firstly, the physical mechanisms of the AC heat generation and 
the crucial physical parameters for enhancing the AC heating power of SPNPs are 
discussed. Next, the physical contribution of Néel and Brown relaxation loss power to 
the total AC heat generation power of ferrofluids with SPNPs (soft and hard ferrite 
SPNPs) is investigated. Chapter 6 focuses on developing a promising new MFH agent 
for local induction of HSPs 72. The magnetic properties and AC heating 





 cations concentration on the AC/DC magnetic properties, AC heat 
generation characteristics, and biocompatibility of the MnxZn1-xFe2O4 SPNPs are 
experimentally and physically investigated. Chapter 7 investigates the feasibility of 
the engineered Mn0.5Zn0.5Fe2O4 SPNPs to a MFH agent application, and demonstrates 
the effectiveness of MFH for highly efficient local induction of HSPs 72 in RGCs. 
The improved AC heating characteristics and cellular uptake efficiency of the 
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engineered Mn0.5Zn0.5Fe2O4 SPNPs and their physical reasons are discussed. The 
biotechnical approaches of MFH to enhance the induction efficiency of local HSPs 72 
are also presented. In addition, a newly designed infusion technique to inject the 
SPNPs into the retina layer will be presented. Finally, chapter 8 concludes with a 
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CHAPTER 2 LITERATURE REVIEW 
This chapter introduces some of the basic theories and concepts and provides a 
review of the previous works directly relevant to the research fields conducted in this 
thesis. Firstly, glaucoma and current therapy methods including ocular 
neuroprotection are reviewed. Secondly, current HSPs induction methods and their 
limitations are introduced. Thirdly, the theory and development of magnetic fluid 
hyperthermia (MFH) and ferrofluid (fluidic SPNP) agents are presented. Lastly, AC 
magnetically-induced heating mechanisms of MFH are presented. 
 
2.1 Glaucoma – Causes, Symptoms, and Current Therapy Methods 
Glaucoma is called the “silent thief of sight” because it is painless and symptoms 
are occurred when vision loss is quite advanced. This disease has been considered to 
be one of the most fatal diseases responsible for irreversible blindness, which is 
affecting approximately 2 % of the world population over the age of 40 [1-5]. 
Glaucoma is a progressive and devastating optic neuropathy. Although, the exact 
cause of glaucoma is still not clear, the damage of optic nerve and selective loss of 
RGCs and their axons have been considered to be a main cause [4-7]. Glaucoma is 
mainly classified into two types. The first type is open angle (chronic) glaucoma, 
 
Figure 2-1 Progressive loss of vision caused by glaucoma [6] 
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which is the most common form of glaucoma, and the second one is closed angle 
glaucoma (Fig. 2-2). The progression of open angle glaucoma is very slow and it 
destroys vision gradually without pain and obvious symptoms, therefore an early 
diagnosis for open angle glaucoma is difficult to make. On the other hand, closed 
angle glaucoma triggers acute angle-closure which is accompanied by obvious 
symptoms such as sudden ocular pain, red eye, and sudden decreased vision [7,8]. 
 Glaucoma is generally diagnosed by testing of intraocular pressure, IOP, 
(tonometry), shape and color of the optic nerve (ophthalmoscopy), thickness of the 
cornea (pachymetry), field of vision (perimetry), or thickness of nerve fiber layer 
(nerve fiber analysis) [10,11]. Among various testing for glaucoma, ocular 
hypertension, the increase of IOP (normal: 10 ~ 20 mmHg, glaucoma: above 21 
mmHg), caused by reduced drainage of aqueous humor through the trabecular 
meshwork (Fig. 2-2) has been widely accepted for the main risk factor to cause the 
damage of optic nerve and RGCs [2,3,12-16].  
     
 
Figure 2-2 Damage of optic nerve or RGCs caused by increased IOP (left) and open 
angle glaucoma and closed angle glaucoma (right, red arrows: aqueous humor)[9] 
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The increased IOP can be lowered by taking a medicine or by doing surgical 
operation. Various medications (Pilocarpine, Epinephrine, Tomolo maleate, Diamox, 
and Mannitol etc.) are used for the purpose of lowering IOP in clinics however these 
medications have systemic side effects such as visual impairment, diarrhea, and 
paresthesia. Surgical operations (Iridotomy, Trabeculectomy (Fig. 2-3), and insertion 
of shunt or stent (Fig. 2-4)) are also widely used in clinics however the operations are 








Figure 2-3 Created new channel for more normal flow of aqueous humor by 
trabeculectomy [Graphic available: http://www.allaboutvision.com/conditions/ 
glaucoma -surgery.htm] 
 














Figure 2-4 The SOLX deep light glaucoma treatment system combines a 
titanium sapphire laser with a gold shunt (shown at far left next to a quarter 
and at right inserted into an eye). At lower left and right are photos of a 
patient’s trabecular meshwork before and after treatment [Graphic available: 
http://www.allaboutvision.com /conditions/glaucoma-surgery.htm] 
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2.2 Ocular Neuroprotection in Glaucoma 
 Neuroprotection is defined as a therapeutic method to prevent the neurons against 
programmed death or progressive loss (injury) of neurons, neurodegeneration, in the 
central nervous system (CNS) [5,17], and it has been widely accepted as one of the 
most effective therapeutic approaches for the neurodegenerative diseases [18-21]. 
 Recently, the interest in glaucoma treatment has been shifted toward 
neuroprotection to inhibit the progression of loss (damage) of RGCs, axons, and optic 
nerves (ocular-neuroprotection). Among the several existing neuroprotective 
approaches, the drugs (neuroprotective inhibitors or receptor)-based approach has 
been widely studied. As a result, various neuroprotective drugs were attempted to 
prevent the damaged RGCs from the progressive loss or death and some drugs were 
proven to inhibit the progress of death or loss of RGCs [5, 22, 23]. For instance, 
Chaudhary and his co-workers demonstrated that MK801 (dizocilpine) has ocular 
neuroprotective effect in glaucoma [24]. Guo et al. also reported several receptors 
(NMDA, Kainate, and Alphaamino-3-hydroxy-5-methyl-4-isoxazole propionic acid 
(AMPA)) and demonstrated their ocular neuroprotection effect [25]. However, they 
have not been applied to clinical trials, because MK801 is toxic and can induce acute 
neuronal vacuolization as well as the exact mechanism and role of the drugs for 
protecting RGCs from damage or death are still unclear. Moreover, over-dose or 
nonlocal-dose of the drugs can be another cause of RGCs death and can impede the 
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2.3 Heat Shock Proteins (HSPs) 
2.3.1 Ocular Neuroprotective Effect of HSPs 70 and 72 families 
 The induction of HSPs has been recently considered to be a new powerful 
modality for the ocular neuroprotection in glaucoma [26-28]. The HSPs, called by 
stress proteins, are a group of proteins that exist in all of the living creatures covering 
bacteria to human beings. HSPs can be induced in living cells by applying various 
stresses such as thermal stress (hyperthermia), metabolic stress, or oxygen deprivation 
[29,30]. HSPs are classified according to their molecular weight (kDa). Among the 
various families of HSPs, HSPs 70 or 72 (kDa) families in the mammalian CNS have 
been known to enhance neuronal tolerance against ischemic insults and light induced 
damage [26,28,31-33]. In particular, neurons including induced HSPs 72 have been 
shown to be more resistant to seizures in transgenic rat models [34, 35], and the 
stronger ocular neuroprotective effect of HSPs 72 against ischemic and excitotoxic 





Figure 2-5 Schematic diagram of induction of HSPs [Graphic available: 
http://image.thelancet.com/extras/02art9148web.pdf ] 
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2.3.2 Current Methods for Induction of HSPs and Limitations 
 After the first demonstration of the effects of HSPs 72 on ocular neuroprotection 
[27], the research efforts to apply the induction of HSPs 72 for ocular neuroprotection 
have been intensively focused on improving the technical effectiveness in the 
glaucoma clinics. For instance, whole body hyperthermia, intraperitoneal zinc 
injection, and intraperitoneal geranylgeranylacetone injection methods have been 
attempted to induce HSPs 72 in the RGCs using animal model studies [36,37]. 
However, although these trials successfully demonstrated the induction of HSPs 72 in 
RGCs, the whole body hyperthermia was found to excessively induce HSPs 72 in the 
entire body causing to overexpression in the immune system, and the intraperitoneal 
zinc and geranylgeranylacetone injections were accompanied by chemical side effects. 
Therefore, in order to reduce the undesirable side effects, a local HSPs 72 induction 
using a local laser was developed and applied for transpupillary thermotherapy (TTT), 
but although this technical approach successfully produced localized HSPs 72 in the 
  
 
Figure 2-6 Schematic diagram of whole body hyperthermia to induce HSPs (left) 
and fundus photographs after laser irradiation with different powers (right): at 
high powers (> 120 mW), peripapillary whitening was observed in all treated eyes 
[36] 
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optic nerve head, it also suffered from deformation of optic nerve head structure, a 
slight whitening of peripapillary tissue, and photocoagulation in the blood vessels due 
to the high power of the laser and the difficulty in controlling the local temperature 
(Fig. 2-6) [38]. Therefore, a new modality for the biologically & physiologically safer 
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2.4 Hyperthermia 
 Hyperthermia is a type of therapy (thermal therapy) in which body tissues or 
organs are exposed to high temperature to stimulate the tissues (or cells) or to kill 
cancerous cells. Generally, application areas of hyperthermia can be classified into 
three types depending on the applied treatment temperatures: 1) induction of HSPs 
(treatment temperature: 39 ℃ ~ 41 ℃, for conservation of neurons or genetic system 
existing in every organism), 2) cancer treatment (treatment temperature: 42 ℃ ~ 45 ℃, 
often used in conjunction with chemotherapy or radiotherapy), and 3) cancer 
thermoablation (treatment temperature: 50 ℃ ~ 51 ℃, used alone) [39,40]. 
 From the viewpoint of the clinical approaches of hyperthermia, three main 
clinical approaches (local, regional, and whole-body hyperthermia) depending on 
location and depth of the target sites are currently being studied [40-42]. 
 
 
Figure 2-7 An example of equipment of superficial and interstitial hyperthermia [42] 
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 In local hyperthermia, the heat is applied to a small area (usually tissue or tumor 
itself located subcutaneously) using various heat delivering techniques such as 
microwave, radiofrequency, and ultrasound. Figure 2-7 shows an example of 
equipment for superficial and interstitial hyperthermia and figures 2-8 (a), and (b) 
show the superficial microwave hyperthermia, and interstitial hyperthermia, 
respectively. In regional hyperthermia, the heat is applied to larger areas of the body 
such as cavities, organs, or limbs. Three techniques are mainly being used: 1) deep 
tissue approaches for cervical or bladder cancer, 2) regional (thermal) perfusion for 
cancers in the limbs, and 3) continuous hyperthermic peritoneal perfusion (CHPP) for 
cancers within peritoneal cavity [41,42]. Whole-body hyperthermia is used to treat 
metastatic diseases such melanoma, soft tissue sarcoma or ovarian cancer [43] where 
thermal chambers or hot water blankets can be used to deliver the heat (Figs. 2-9 (a) 
and (b)).  
 
 
Figure 2-8 (a) Superficial microwave hyperthermia of malignant melanoma of the skin, 
(b) interstitial hyperthermia in a radical treatment of right breast cancer [42] 
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Figure 2-9 An example of (a) thermal chamber and (b) hot water blanket for whole-body 
hyperthermia 
 
 However, these hyperthermia modalities are usually used with other assisting 
methods such as chemotherapy or radiotherapy which can induce the chemical or 
systemic side effects, as well as they can kill healthy cells due to a difficulty of the 
targeted cell differentiation from healthy cells and deleterious physiological response 
caused by the heat induction of the cells under the high AC magnetic or electric field 
[40,44]. Accordingly, in order to solve these biotechnical problems, in-vivo magnetic 
hyperthermia using ferrofluids with superparamagnetic nanoparticles (magnetic fluid 
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2.5 Magnetic fluid hyperthermia (MFH) 
2.5.1 Introduction 
 In 1957, Gilchrist and his co-workers reported the first application of magnetic 
materials for hyperthermia (magnetic hyperthermia) [44]. They heated lymph nodes 
and several tissues for the purpose of killing cancerous cells using various sized (20 ~ 
100 nm) γ-Fe2O3 particles that exposed to an applied magnetic field of 178 Oe ~ 255 
Oe and frequency of 1.2 MHz. Since then, there have been a number of theoretical 
and experimental research activities to improve the magnetic hyperthermia [45]. 
 The systematic investigation of ferrofluids for a magnetic hyperthermia agent 
application (magnetic fluid hyperthermia (MFH)) was conducted by Jordan et al., in 
1993 [46]. In this study, they experimentally measured the heat generation of various 
sized Fe3O4 and composite ferrite particles (diameter: 3 nm ~ 100 μm) dispersed in 
aqueous solution (Fig. 2-10), and confirmed the high performance of the ferrofluids 
 
 
Figure 2-10 Experimental set-up for AC heat measurements of ferrofluids [46] 
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with ferrite superparamagnetic nanoparticles (SPNPs) to generate the AC 
magnetically-induced heat under an applied AC magnetic field (fappl: 530 kHz, Happl: < 
163 Oe). This research work demonstrated a possibility that the MFH using SPNPs 
ferrofluids can be used in an in-vivo environment to increase the temperature of 
tissues or organs to induce HSPs or to treat cancers without the assistance of other 
therapy methods. Since then, many research activities have been conducted to develop 
and to improve the ferrofluids with SPNPs because the SPNPs have been expected to 
show various physical, chemical, and biotechnical advantages in MFH such as: 1) 
local injection into the targeted cells or organs through various injection methods due 
to high stability (minimal aggregation) and easy control of particle size, 2) easy 
transport to the targeted cells by externally controlled magnetic field, 3) small heat 
loss during hyperthermia due to generation of the AC heat in the inside of cells, 4) 
possibility for differentiation of targeted cells from health cell by using 
antibody-antigen biological reaction [47]. 
 The first clinical trials of MFH were also performed by Jordan et al., in 2005. In 
the clinical trials, they tried to treat mainly prostate and breast cancers using the 
ferrofluids with Fe3O4 SPNPs and found that the MFH was feasible [48-53]. However, 
it was also found that further refinement of the SPNPs agent and the injection 
technique is necessary to optimize distribution of injected SPNPs agents for the 
uniform temperature profile in the targeted tissue and to improve the AC heating 
temperature with heating up rate. At present, MFH is being widely considered to be a 
main local in-vivo hyperthermia modality. Therefore, many theoretical and 
experimental activities are being made to develop more powerful fluidic SPNPs 
agents and to improve bio-techniques including SPNPs injection technique. 
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2.5.2 Ferrofluids with SPNPs for MFH 
 Ferrofluids are the colloidal suspensions which are including surface modified 
ferrite SPNPs (Fig. 2-12) [54]. The preparation process of ferrofluids can be divided 
into two steps: 1) synthesis of nano-sized magnetic particles such as Fe-ferrite, 
Co-ferrite, Ni-ferrite, MnZn-ferrite, NiZn-ferrite nanoparticles or CuNi, Gd-, Ca-, and 
La-complexes etc. [55-58] that can be synthesized by using microemulsion [59], 
co-precipitation [60], ball milling [61], sonochemical [62], sol-gel [63], and thermal 
decomposition [64], 2) coating and dispersion of the synthesized nanoparticles in 
various carrier liquids. 
 Currently, various magnetic ferrite nanoparticles (MFe2O4, M = Fe, Ni, Co, Mn 
etc.) [65,66] and some alloys (FePt, NiPt, and NiPd) [67,68] are being mainly used in 
ferrofluids for MFH agent applications. The pure magnetic materials such as Co, Ni, 
 
 
Figure 2-11 Injection of ferrofluid into the prostate [47] 
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and Fe can also be used in ferrofluids. However, they have some limitations to be 
used for bio-application because they are toxic and very sensitive to oxidation [69]. 
 The most important characteristic of ferrofluids for MFH agent applications is 
their colloidal stability. If the magnetic interaction energy (such as magnetic field 
energy, dipole-dipole interaction energy) or attractive force (such as Van der Waals 
force) between magnetic particles dispersed in fluids is stronger than the thermal 
energy due to Brownian motions of the particles ET = kBT (kB: Boltzmann’s constant, 
T: absolute temperature), the aggregation will occur (Table 2-1) [70-72]. This is 
strongly dependent on the size and size distribution, coating and dispersion statuses, 
magnetic nature of the particles, and temperature [70]. In addition, the particles can be 
aggregated due to gravitational energy (Eg). The gravitational energy of the particles 
in the gravitational field is 
 
 
Figure 2-12 Formation of colloidal suspension [Sharifi et.at., J. Magn. Magn. 
Mater. 324 , 903 (2012)] 
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6/3dghEg                                                 (2-5-1) 
  
where Δρ is the density difference between the particles and the carrier liquid, g is the 
gravitational acceleration, and h is the height of particle of diameter d form the bottom 
of container. For gravitational stability of particles in fluids, the maximum size of 
particles is in order of 10 nm [74]. Therefore, for colloidal stability of particles in 
fluids, SPNPs (no spontaneous magnetization after removing an applied magnetic 
field, Fig. 2-12) with a narrow size distribution are necessary and they should be 
uniformly and singly coated. In addition, the coated SPNPs should be well dispersed 
in fluids with a higher mono-dispersity (lower poly-dispersity index, PDI) [66]. 
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Table 2-1 Various forces acting in a ferrofluids [70-72] 
(V: volume of particle, H: external magnetic field, M0: spontaneous magnetization, μ0: magnetic 
constant, m: magnetic moment, r: inter-particle distance, l: distance between particles, and A: 
Hamaker constant) 
Interaction Force Equation 
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2.6 AC Magnetically-Induced Heat Generation of SPNPs 
2.6.1 Choices of magnetic materials 
 When a magnetic materials is placed in a magnetic field of strength of H, the 
individual atomic in the magnetic material contribute to its overall response, the 
magnetic induction is given by Eq. (2-6-1): 
 
B = μ0(H+M)                                                    (2-6-1) 
 
where μ0 is the permeability of the free space, and M is the magnetic moment per 
volume (M = m/V, m: magnetic moment, V: volume). The magnetic materials may be 
conveniently classified in terms of their volumetric magnetic susceptibility, χ, (Eq. 
2-6-2). 
 
M = χ H                                                        (2-6-2) 
 
Most materials display magnetism only in the presence of an applied H, and show 
very small magnetism. They are classified as paramagnets (χ: positive and small 
~10
-5
) or diamagnets (χ: negative and small ~ -10-6). However, some materials have 
ordered magnetic spins and are magnetic without requiring an applied H. These 
materials are classified as ferromagnets (χ: positive and very large), ferrimagnets (χ: 
positive and very large), and antiferromagnets (χ: positive and small) (Fig. 2-13) [75].  
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 The ferromagnetic and ferrimagnetic materials show hysteresis loops when an 
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Figure 2-13 Kinds of magnetism 
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related to the magnetic crystalline anisotropy and the pinning of magnetic domain 
walls. The shape of the hysteresis loops can be determined by particle size (Fig. 2-14 
and Fig. 2-15). Larger particles can have a multi-domain ground state which leads to a 
narrow hysteresis loop since it takes relatively small field energy to move the domain 
walls [76, 77]. With decreasing the particle size, the domain wall becomes 
energetically unfavorable and there is a transition from the multi-domain particle to 
the single-domain particle. In this case, the magnetization reversal is determined by 
uniaxial anisotropy (Stoner and Wohlfarth model [80]) which leads to a broad 
hysteresis loop [76, 77, 80]. In the case of much smaller size of particles (d = ~ the 
order of tens nm or less), they can show superparamagnetism, where the magnetic 
moments (spins) of the particles fluctuate in response to thermal energy, while the 
individual atomic magnetic moments are maintained [78]. 
   
2.6.2 Superparamagnetism 
 Superparamagnetism is a phenomenon by which magnetic materials exhibit a 




Figure 2-14 Hysteresis loops of (left) single-domain (smaller particle) and 
multi-domain (larger particle) and (right) superparamagnetic depending on the 
size of particle [76] 
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the energy to change the direction of magnetic moment of a magnetic material. 
Superparamagnetism is shown when the magnetic material is composed of very small 
crystallites. Therefore, the underlying physics of superparamagnetism can simply be 
understood by considering the physical relationship between the size and the 
anisotropy energy of particle [78]: 
 
E(Ɵ) = KV sin2Ɵ                                  (2-6-3) 
 
where V is the particle volume, K is the anisotropy constant, and Ɵ is the angle 
between the magnetization and the easy axis. The anisotropy energy is responsible for 
maintaining the magnetic moments along a certain direction in the particles. With 
decreasing particle size, however, the thermal energy, kBT, exceeds the energy barrier, 




Figure 2-15 Effect of particle size on the magnetic coercivity [77] 
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orientation of the magnetic moment) and, eventually, the particle has a paramagnetic 
property.  
 
2.6.3 AC heat generation mechanisms 
 Magnetic nanoparticles being subjected to an AC magnetic field can generate AC 
magnetically-induced heating by converting the AC magnetic field into heat during 
magnetization reversal process. The AC heat generation of the magnetic nanoparticles 
is due to the different processes of magnetic losses occurring in the particles system: 
1) hysteresis loss, 2) Néel relaxation loss, and (3) Brown relaxation loss (in viscous 
suspensions) [79]. 
 Hysteresis loss can be determined by integrating the hysteresis area of the larger 
(multi-domain and sing-domain) nanoparticles. However, when the particle size is 
decreased to the critical size, the barriers (Eq. 2-6-3) for magnetization reversal are 




Figure 2-16 Illustration of the two components of the magnetic relaxation  
of nanoparticles 
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(Superparamagnetic region). In this case, the hysteresis loss becomes negligible [39].
 AC magnetically-induced heating from the small particles (superparamagnetic 
nanoparticles) is mainly caused by the delay in the relaxation of the magnetic moment 
through either Néel relaxation (the rotation of magnetic moment within the particle) 
or Brown relaxation (the rotation of the particle itself in a viscous solution) (Fig. 2-16) 
[39, 79,81].  
 The Néel relaxation time (τN) of a nanoparticle is given by the ratio of the 
anisotropy energy, KV, to the thermal energy, kT (Eq. (2-6-4)) [82,83] 
 
)10()],/(exp[ 900 skTKVN
  .                               (2-6-4) 
 
 In a fluid, the relaxation time of the nanoparticles is characterized by a viscosity 
(η) and a hydrodynamic volume (VH) of the nanoparticles dispersed in the fluid 
(Brown relaxation time, τB, Eq. 2-6-5), and a second relaxation mechanism occurs due 









 (VH = hydrodynamic volume)                             (2-6-5) 
  
 In the general case, the faster relaxation time (between the τN and τB) becomes 
dominant and the effective relaxation time (τeff) is defined by [82,83] 
 
BNeff  /1/1/1  .                                             (2-6-6) 
 
Figure 2-17 shows that the shorter relaxation time tends to dominate in determining 
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the effective relaxation time for any given size of particle [79]. The relaxation time 
also depends on the anisotropy constant and viscosity of fluids as well as the particle 








Figure 2-18 Relaxation times of magnetic moment orientational dynamics as a 
function of particle diameter and viscosity. 
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 The AC magnetic field response characteristics of the relaxation of the 
nanoparticles can be investigated by measuring of the complex susceptibility (χ = χ m´ 
(in-phase) + iχ˝m
 
(out-of-phae)). In particular, the χ˝m (loss component of 
susceptibility) of the complex susceptibility which is directly related to the effective 

















00 kTVM s  ,(Ms = saturation magnetization). (2-6-7) 
 
 The physical relationship between χ˝m and relaxation loss power (Prelaxation loss) of 
nanoparticles was derived by Rosensweig [79] and it is expressed by Eq 2-6-8.  
 
.2//0 fHP lossrelaxation                                        (2-6-8) 
 
According to the above equations, the Prelaxation loss is squarely proportional to the 
applied magnetic field and linearly proportional to the frequency at low frequency 
(2πfτeff ≤ 1) while the Prelaxation loss approach a frequency independent at high frequency 
(2πfτeff >> 1). 
 
2.6.4 Specific loss power 
 The main parameter for determining the AC heat generation ability of 
nanoparticles (ferrofluids) in an in-vivo environment is the specific loss power (SLP). 
For an effective MFH with minimal damage to healthy cells, the nanoparticle agents 
should generate the sufficiently high AC magnetically-induced heating temperature 
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with fast heat-up time as well as the amount of nanoparticles for injection should be as 
low as possible. These requirements of the nanoparticles can be evaluated by 
analyzing the SLP that is obtained from Eq. 2-6-9 and the measured AC 














                                              (2-6-9) 
 
where, Ci is volumetric heat capacity of each component in the system, mi is mass of 
each component in the system, 
42OMFe
m is mass of the each magnetic nanoparticle, and 
T  and t  are the 63 % change in temperature at maximum temperature and the 
corresponding change in time, respectively. 
 In addition to the applied AC magnetic field, SLP of the nanoparticles is strongly 




Figure 2-19 Temperature rise rate in polydisperse ferrofluid with Fe3O4 
nanoparticles 
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a very sharp maximum of the SLP in Fe3O4 nanoparticles and also found that an 
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CHAPTER 3   EXPERIMENTAL TECHNIQUES 
This chapter presents the experimental techniques used in this thesis. The first 
and second sections provide the SPNPs synthesis and coating processes. The next 
section presents an overview of the equipment utilized in the research to investigate 
the various characteristics of the solid and fluid state SPNPs. These include magnetic 
property, AC heating characteristics, and dispersion status. Finally, detailed 
experimental processes for investigating bio compatibility of the SPNPs and local 
HSPs induction behavior are presented. 
 
3.1 Synthesis of SPNPs – High Temperature Thermal Decomposition 
Method 
3.1.1 Introduction 
The SPNPs used in the thesis were synthesized by using a high temperature 
thermal decomposition (HTTD) method [1] and a modified HTTD method (for 
synthesis of engineered Mn0.5Zn0.5Fe2O4 SPNPs, EMZF-SPNPs) in which the 
chemical potential of cations was changed by controlling the thermal energy during 
the conventional HTTD synthesis process. The synthesis method involves the 
decomposition of metallic precursors in the presence of hot organic surfactants and 
solvents. The basic principle of this method is to initiate chemical reactions between 
reagents in solvent and control the nucleation and growth of the reactants (SPNPs) by 
changing thermal energy in the solution. The HTTD method offers the distinct 
advantages that it allows to control the size and size distribution, as well as the 
magnetic properties and AC heating characteristics of the SPNPs. Another advantage 
is that this kind of chemical-based synthesis method can be easily scaled up for mass 
production. 
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Figure 3-1 Illustration of HTTD method for synthesis of SPNPs 
 
3.1.2 Preparation of SPNPs 
 The superparamagnetic MFe2O4 (M = Co, Fe, Ni, and Mg) and MnxZn1-xFe2O4 
nanoparticles were synthesized by using a conventional HTTD or a modified HTTD 
method. Ni (II) acetatetetrahydrate [(C2H3O2)2Ni4H2O] (99.998 %), Co (II) 
acetatetetrahydtrate [(C2H3O2)2Co4H2O] (99.999 %), Mg acetatetetrahydtrate 
[(C2H3O2)2Mg4H2O] (99.999 %), Fe(III) acetylacetonate [(C5H8O2)3Fe] (> 99.9 %), 
Mn(II) acetatetetrahydrate [(C2H3O2)2Mn4H2O] (99.99 %), Zn acetatedihydrate 
[(C2H3O2)2Zn2H2O] (99.999 %), 1,2-hexadecanediol [CH3(CH2)13CH(OH)CH2OH] 
(90 %), oleic acid (90 %), oleylamine (70 %), and benzyl ether (99 %) were 
purchased from Aldrich Chemical Co. For the synthesis of MFe2O4 (M = Co, Fe, Ni, 
and Mg) and MnxZn1-xFe2O4 nanoparticles, Co (1 mmol), Fe (2 mmol), Ni (1 mmol), 
Mg (1 mmol), Mn (0.1 mmol ~ 0.9 mmol), Zn (0.1 mmol ~ 0.9 mmol), Ni (0.5 mmol), 
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1,2-hexadecanediol (10 mmol), oleic acid (6 mmol), oleylamine (6 mmol), and benzyl 
ether (20 mL) were mixed and magnetically stirred. In a conventional HTTD method, 
the mixed solutions were heated to 200 C ~ 203 C for 30 min (~ 6 C/min, the first 
ramping up rate) and maintained for another 30 min (nucleation step). Then, the 
solutions were heated again up to 296 C, which is a boiling point of benzyl ether, for 
6 min ~ 8 min (16 C/min ~ 14.5 C/min, the second ramping up rate) and maintained 
for 30 min (growth step). However, in the case of the modified HTTD method, the 
first ramping up rate, and the heat treatment time in the nucleation step (process 
temperature: 200 C ~ 203 C) were changed up to 10 C/min ~ 11.2 C/min, and 58 
min ~ 60 min, respectively from the conventional HTTD method. The heat treatment 
time in the growth step (process temperature: 296 C) was adjusted to 46.5 min to 
control the mean particle diameter of nanoparticles below 10 nm. After removing the 
heat source, the mixed solutions were cooled down to room temperature and ethanol 
(40 mL) was subsequently added to the solutions under ambient condition. The 
synthesized products (black or brown color depending on materials) were rinsed, 
precipitated, and separated using a centrifuge. The products were dissolved in hexane 
(15 mL) mixed with ethanol (30 mL) and were magnetically stirred again for 30 min 
to remove organic residues. After centrifugation with a 6500 rpm was applied for 12.5 
min, the nanoparticles were collected and dried at room temperature. Figure 3-2 
shows the procedure of HTTD method. 
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3.2 Coating of SPNPs with Amorphous Silica and Polyethylene Glycol 
for Ferrofluids 
 The synthesized SPNPs were coated with bio-compatible dimercaptosuccinic acid 
(DMSA), amorphous silica (silica) or polyethylene glycol 500Da (PEG) to form 
ferrofluids. The coating layer on surface of SPNPs expects to prevent the SPNPs form 
aggregation in fluids and to improve their biocompatibility [2], and it allows for 
providing the SPNPs with bio-functional surface leading to covalently attaching 
specific ligands to the surface of the SPNPs for cell differentiation [3,4]. In addition, 
the coating layer can improve cellular uptake characteristics of SPNPs because it has a 
good cell adhesion property, a non-immunogenic characteristic, and a high solubility 
in cell membranes [5]. 
 For coating the SPNPs with DMSA, a 10 mg of SPNP were dissolved in 1 ml of 
toluene and DMSA molecules (~ 10 mg) were dissolved in 1 ml of dimethyl sulfoxide 
(DMSO). We mixed these two solutions and allowed them to react at ~ 25 C 
overnight. After isolation of black powders through centrifugation, a 1 ml of water 
was added and then adjusted the pH of the solution to be ~ 7. In order to coat the 
SPNPs with silica, a 20 mg of the synthesized SPNPs were first dispersed into a 
mixed solution of cyclohexane [C6H12 (99.5 %)] (50 ml), Igepal [(C2H4O)nC15H24O] 
(0.23 ml), and ammonium hydroxide [NH4OH (28 %)] (0.26 ml) under sonication 
together with stirring for 2 hours. Subsequently, various amount of tetraethoxysilan 
[C8H20O4Si (98 %)] was added into the mixture containing the synthesized SPNPs and 
the reaction was allowed to proceed at room temperature for 1 hour under continuous 
sonication with stirring. The concentration of tetraethoxysilan was varied from 1 ml to 
3 ml to control the thickness of silica coating layer from 2 nm to 7 nm (Fig. 3-3). For 
coating the PEG layer, the surface of the synthesized SPNPs was first modified by 
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oleic acid [C18H34O2 (90 %)] to minimize aggregation during PEG coating process [6], 
and then the modified SPNPs were dispersed in toluene [C7H8 (99.3 %)] (7.5 mL) 
with vigorous agitation. After 2 hours agitation, triethylamine [C6H15N (99 %)] (3.75 
mL) and methoxy-PEG-silane 500 Da (0.75 mL) were added to the toluene containing 
the SPNPs, and the mixed solution were well agitated for 24 hours at room 
temperature. The PEG coated SPNPs in the solution were washed with ethanol (3 
times) and dispersed in D.I. water to form ferrofluidic solution. Figure 3-3 shows the 
TEM images of silica and PEG coated MnxZn1-xFe2O4 SPNPs (coating thickness: ~ 2 
mn) and ferrofluids with PEG, DMSA, and silica coated SPNPs used in this thesis. 
 
 
   
Figure 3-3 TEM images of silica and PEG coated MnxZn1-xFe2O4 SPNPs (coating 
thickness: ~ 2 mn) and ferrofluids with PEG, DMSA, and silica coated SPNPs 
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3.3 SPNPs MFH Agents Characterization Techniques 
3.3.1 Transmission of Electron Microscope (TEM) 
 Transmission of electron microscope (TEM) is a very powerful system for 
obtaining morphology and crystallographic information of materials. In particular, a 
TEM is an essential system to observe and to analyze size, size distribution, shape, 
and crystal structure of solid state SPNPs as well as dispersion and coating status of 
coated SPNPs due to the very small size of SPNPs (diameter : < 10 nm). A TEM 
consists of an electron gun, a specimen chamber, a vacuum system, and condenser, 
objective, and projector lenses. The condenser lens concentrates and focuses the 
 
 
Figure 3-4 Schematic diagram of structure of TEM [8] 
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electron beam that comes from the electron gun onto the sample. The objective lens 
that is the most important lens forms the enlarged image of the sample in an image 
plane. This enlarged image is more enlarged by the projector lens. The TEM shows an 
image of sample through differential contrasts. The image of the sample is formed by 
the transmitted electron beam that make the bright field image and by the deflected or 
diffracted electron beam that the make dark field image [7]. It is also possible to 
observe the crystalline structure and symmetry of the lattice in a crystalline sample by 
choosing the selected area diffraction (SAED) mode. 
 
3.3.2 Vibrating Sample Magnetometer (VSM) 
 The magnetic properties such as major magnetic hysteresis loops, minor magnetic 
hysteresis loops, and initial magnetization curves of SPNPs were investigated by 
using a vibrating sample magnetometer (VSM), LS 7407 from LakeShore (shown in 
Fig. 3-5). The system generates a uniform magnetic field up to 25.1 kOe (2.51 T). 
 
 
Figure 3-5 LS 7407 VSM system 
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VSM is the most widely used for characterizing magnetic materials (including thin 
films, nanoparticles, and bulk-materials). The magnetic hysteresis loops are obtained 
my mapping the magnetization of sample that is mounted on a sample holder placed 
inside a uniform magnetic field to magnetize the sample and physically vibrated at a 
constant frequency in the vertical direction. The change of magnetic flux caused by 
the vibrating of sample induces an AC current in the pickup coils with an effective 
voltage (Faraday’s law of induction) that is proportional to the sample’s magnetic 
moment. In this research, measurement of the magnetic properties of SPNPs were 
performed by placing 5 ~ 8 mg of sold state SPNPs in a VSM holder at room 
temperature. The applied magnetic fields were ± 15 kOe (for major hysteresis loop), 
and ± 80 or ± 140 Oe (for minor hysteresis loop), respectively. 
 
3.3.3 X-ray diffraction (XRD) 
 The structural properties of spinel ferrite SPNPs were analyzed and confirmed by 
using a Cu-kα radiated X-ray power diffraction (XRD). XRD is a common technique 
for the investigation of detailed information on crystallographic structure and 
chemical composition of samples. XRD is based on constructive interference of 
monochromatic X-rays and a crystalline sample. The interactions between the incident 
X-rays and sample generate the constructive interference when they satisfy Bragg’s 
Law (2d sinƟ=nλ, Fig. 3-6) [9] which relates the wavelength of the incident wave (λ) 
to the diffraction angle (Ɵ) and the spacing (d) between the planes in the atomic 
lattice. These diffracted X-rays and their intensities are detected. By varying the 2Ɵ 
angles, all possible diffraction directions of the lattice of samples can be obtained. 
 Figure 3-7 shows the XRD results of all the synthesized superparamagnetic 
nanoparticles used in this thesis. As can be seen in the result, the synthesized 
CHAPTER 3   EXPERIMENTAL TECHNIQUES 
54 
superparamagnetic nanoparticles did not have any undesirable crystalline phase, but 






Figure 3-7 XRD patterns for all the nanoparticles used in this thesis 
 
 
Figure 3-6 Bragg diffraction. Two incident waves with identical wavelength and 
phase approach a crystalline solid ant are scattered off two different atoms within 
it. The lower beam traverses an extra length of 2dsinƟ. Constructive interference 
occurs when this length is equal to an integer multiple of the wavelength of the 
radiation. 
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 3.3.4 Physical Property Measurement System (PPMS) 
 Physical property measurement system (PPMS, Quantum Design Fig. 3-8) was 







susceptibility, χ//m: out-of-phase susceptibility). The χ
//
m is directly relevant to the AC 
magnetically-induced heating generation of SPNPs. The PPMS consists of a liquid He 
cooled dewar, containing a super-conducting magnet and a measuring probe. A variety 
of magnetic, DC/AC electrical and thermal properties can be measured from 4 K to 
400 K using different measurement systems. Sample is mounted on a 2.3 cm diameter 
puck that is inserted into the measurement chamber by a rod and connected at the 
bottom of the dewar to the measuring systems. Sample can be in the form of solids 





Figure 3-8 Physical property measurement system, Quantum Design 
 
CHAPTER 3   EXPERIMENTAL TECHNIQUES 
56 
3.3.5 Magnetic Property Measurement System (MPMS) 
 Magnetic property measurement system (MPMS, Quantum Design) is designed to 
study magnetic properties of materials. It employs SQUID (super conducting quantum 
interference device) technology for achieving superior measurement sensitivity, 
dynamic range, and reproducibility otherwise unattainable. MPMS was used in this 
study to investigate a superparamagnetic characteristic of nanoparticles. The 
superparamagnetic nature of nanoparticles was confirmed by investigating the 
blocking temperature (TB) that was obtained from the magnetization behaviors of 
nanoparticles depending on environment temperature controlled from 4 K to 340 K. 
 
3.3.6 Measurement of AC Magnetically-Induced Heat Temperature 
 The AC magnetically-induced heating temperatures (TAC,mag) of solid state and 
coated SPNPs (fluid state) were measured by using a specially designed AC magnetic 
field generation system which consists of AC coils, capacitors, DC power supplies, 
wave generators, optical thermometers, and a control system as shown in Fig. 3-9. 
The AC magnetic field generation system operates at a wide range of frequencies (30 
kHz ~ 370 kHz) with magnetic field strength up to 170 Oe with no change of the 
capacitor or the AC coil. This is critical to be able to evaluate the AC heating capacity 
of various SPNPs over a wider range of frequencies and magnetic fields because 
SPNPs have the different AC heat generation ability, which is depending on material, 
size, size distribution, and dispersion status. 
 The total amount of solid state SPNPs for measuring the AC heating 
characteristics was fixed at 60 mg. In order to experimentally obtain the SLP, the 
coated SPNPs were dispersed in various viscous fluids with different concentrations 
and the AC heating temperature of the fluids containing coated SPNPs was measured 
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under the applied AC magnetic field. 
 
 
        Figure 3-9 AC magnetic field generation system 
 
3.3.7 Dynamic Light Scattering System (DLS) 
 The hydrodynamic diameter (dH) and its distribution, polydispersity index (PDI), 
and Z-potential of the ferrofluid with silica and PEG coated SPNPs were measured by 
using a dynamic light scattering system (DLS, Zetasizer Nano ZS System (Fig. 3-10)), 
to investigate the dispersion, aggregation, and surface charge of the coated SPNPs, 
which affect the magnetic, AC magnetically-induced heating characteristic, as well as 
cellular uptake efficiency. 
 DLS (or Photon correlation spectroscopy) is a non-invasive technique for 
measuring the size of molecules or particles typically in the submicron region. 
Particles in fluids (solvent) have Brownian motion that is induced by the 
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bombardment by solvent molecules. If particles are illuminated with a laser, the 
intensity of scattered light is varied depending on the size of the nanoparticles. 
Analysis of the intensity provides the velocity of Brownian motion (diffusivity, D) 
and hence the particle size using the Stokes-Einstein relationship (D=RT/NA6πηru, NA: 
Avogadro number, T: temperature, η: viscosity of the solution, and ru: hydrodynamic 
radius of molecule/particle) [10]. The PDI is defined as the width of the particle size 
(dH) distribution in fluids, which is obtained a cumulants analysis of the DLS 
measured intensity. The Z-potential is the electrostatic potential at outer boundary 
(surface) of particles, which is calculated from the mobility measured during an 







Figure 3-10 Structure of DLS, Zetasizer Nano ZS (Malvern) 
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3.4 Cell Viability and Cellular Uptake of Nanoparticles 
3.4.1 Cell Counting Kit-8 Assay 
 The in-vitro cell viability of uncoated and coated SPNPs was investigated by 
employing the Cell Counting Kit-8 (CCK-8) assay. For cell viability assay, retinal 
ganglion cells (RGC-5, rat) and neuronal stem cells (NSCs, isolated from human fetal 
mid brain) were seeded 2,000 cells/well in 96-well plate. After 24h, cells were 
differentiated with 1 μM staurosporine (Alexis Biochemicals, San Diego, CA) for 1h 
and then treated with various concentrations (0, 1, 3, 5, 10, and 30μg/ml) of SPNPs. 
SPNPs were dispersed into the culture media of 2.5% alcohol. After 24h treatment, 
CCK-8 solution (Dojindo Molecular Technologies, Kumamoto, Japan) was added to 
each well of the plate and evaluated the absorbance at 450 nm using a microplate 
spectrophotometer (Molecular Devices, Spectra max190). All the experiments were 
performed in three wells on three separate occasions. 
 
3.4.2 TEM Study and Cellular Uptake 
 A TEM analysis for the cells treated by the uncoated and coated SPNPs was 
conducted to investigate the degree of nanoparticle penetration into the cells (cellular 
uptake), the cell apoptosis, and the cell deformation including nuclei fragmentation. 
The cells were differentiated with 1μM staurosporine for 1h and incubated with 30 
μg/ml nanoparticle for 24 h. The cells were fixed with 2.5 % glutaraldehyde and 
sequentially washed with PBS (phosphate buttered saline) followed by 0.1M 
cacodylate buffer (pH7.2) and postfixed with 2% osmium tetroxide in 0.1M 
cacodylate buffer for 1.5 h at room temperature. The samples were then washed 
briefly with distilled water, dehydrated in ethanol, infiltrated by using propylene oxide 
(Acros Organics) and EPON epoxy resin mixed (EmBed 812, Nadic Methyl 
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Anhydride , Poly Bed@ 812, Dodecenylsuccinic Anhydride, Dimethylaminomethyl 
Phenol, Electron Microscopy Polysciences), and finally embedded with only epoxy 
resin. The epoxy resin mixed samples were loaded into capsules and polymerized at 
38 ℃ for 12h and 60 ℃ for 48 h. Thin sections were made using an RMC MT-XL 
ultramicrotome and collected on copper grid and were observed by TEM without any 
double staining with 8% uranyl acetate and 4% lead citrate and viewed with either a 
JEOL (JEM-1400) at 80 kV in the TEM mode.  
 The effective mass of coated SPNPs uptake in the RGCs was quantitatively 
determined by an inductively coupled plasma mass spectrometer (ICP-MS). To 
explore the cellular uptake behavior of coated SPNPs with RGCs, the RGCs were 
incubated at a 10 mL of DMEM containing coated SPNPs fluid for 24 hours. 
 
3.5 Identification of Induction of Heat Shock Proteins 72 - Cell 
Staining (Fluorescein Isothiocyanate and 4’, 6-Diamino-2- Phenylindole) 
and Western Blot Analysis 
 The induced HSPs 72 in RGCs were identified by cell staining. After MFH using 
PEG coated EMZF-SPNPs, the cells were counted and seeded in culture plate 
followed by fixation with 10% formaldehyde. The cells were fixed and washed with 
PBST (phosphate buffered saline tween-20) twice, and then blocked. Anti-HSPs 72 
(Enzo life sciences, USA) was added as primary antibody and followed by washing 
with PBST twice, then Alexa fluor 488 goat anti-mouse IgG (FITC, Fluorescein 
isothiocyanate) (Life technologies, USA) was added as secondary antibody and 
washed with PBST twice again. To stain the nucleus, DAPI (4’, 
6-diamino-2-phenylindole) (Sigma, USA) was added and followed by washing with 
PBST twice. The stained HSPs 72 and nucleus in RGCs were observed and analyzed 
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by using a fluorescence microscope. 
 To clearly identify the induction of HSPs 72 by the MFH, we performed the 
Western blot analysis for 4 samples, which were 3 types of control groups (RGCs only, 
RGCs + AC magnetic field (fappl = 140 kHz, Happl = 140 Oe for 900 sec) + no SPNPs, 
and RGCs + SPNPs (500 μg/mL) + no AC magnetic field) and experimental group 
(SPNPs of 500 μg/mL and AC magnetic field (140 kHz, 140 Oe) for 900 seconds. For 
Western blot analysis, the harvested cells were lysed using a lysis buffer (Intron 
Biotechnology, Korea) and loaded onto a 10% SDS-polyacrylamide gel, and then 
transferred to Polyvinylidene fluoride membrane. The membrane was blocked by 
non-fat dry milk and incubated with primary antibody: HSPs 72 antibody (1:1000, 
Enzo life sciences, USA) and ß-actin antibody (1:1000, Sigma, USA). The membrane 
was washed with a Tris-buffered saline containing 0.1% Tween-20 and incubated in a 
goat anti-mouse IgG (1:5000, Santa Cruz, USA). After the membrane was washed, the 
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3.6 Infusion of SPNPs to Retina in Animal Model 
 All procedures used in this study conformed to the principles of the ARVO 
(Association for Research in Vision and Ophthalmology) Statement for the Use of 
Animals Ophthalmic and Vision Research and the protocol was approved by the 
Research Ethics Committee of Seoul National University Hospital. Adult 
(8-week-old) male Sprague-Dawley rats were used. Animals were bred under SPF 
(Specific Pathogen Free) conditions. The animals had free access to food and water, 
and were maintained in temperature-controlled rooms with a 12 hour light/dark cycle. 
For the experimental manipulations, the rats were anesthetized with an intramuscular 
injection of 10 mg/kg zolazepam (Zoletil® , Yuhan Corp., Seoul, Korea) and 14 mg/kg 
xylazine hydrochloride (Rompun® , Bayer, Frankfurt, Germany). 
A newly designed infusion technique was first attempted in this study. In order 
to infuse the EMZF SPNPAs to the surface of retina, the uncoated and silica coated 
EMZF SPNPs were first diluted separately in mixed solution of DMEM (Dulbecco’s 
modified eagle medium), 10 % FBS, 1 % PS (penicillin streptomycin), and 2 mM 
glutamine. And then, a 30 μg/ml of the complexes (10 μL) was injected into the rat 
eyeballs through the vitreous body using a Hamilton syringe needle. The rat eyeballs 
containing the uncoated and silica coated EMZF-SPNPs were extracted and paraffin 
blocks of the eyeballs were created after two weeks later. The study of nanoparticle 
distribution and the histological exam using the paraffin blocks were then carried out 





CHAPTER 3   EXPERIMENTAL TECHNIQUES 
63 
References: 
[1] S. Sun, H. Zeng, D. B. Robinson, S. Raoux, P. M. Rice, S. X. Wang, and G. Li, 
J. Am. Chem. Soc., 126, 273 (2004) 
[2] R. E. Rosenweig, J. Magn. Magn. Mater., 252, 370 (2002) 
[3] Y. Lu, Y. Yin, B. T. Mayers, and Y. Xia, Nano Lett., 2(3), 183 (2002) 
[4] S. T. Selvan, T. T. Tan, and J. Y. Ying, Adv. Mater., 17(13), 1620 (2005) 
[5] M. Yamazaki and T. Ito, Biochemistry, 29, 1309 (1990) 
[6] L. Shen, P. E. Laibinis, and T. A. Hatton, Langmuir, 15, 447 (1999) 
[7] L. Reimer, and H. Kohl, Transmission Electron Microscopy: Physics of Image 
Formation, Springer (2008) 
[8] Wikipedia, available: http://en.wikipedia.org/wiki/File:Scheme_TEM_en.svg 
[9] H. P. Myers, Introductory Solid State Physics, Taylor & Francis (2002) 













CHAPTER 4 PHYSICAL LIMITS OF CURRENT SUPERPARAMAGNETIC Fe3O4 
NANOPARTICLES FOR MFH AGENT APPLICATIONS 
 64 
CHAPTER 4 PHYSICAL LIMITS OF CURRENT 
SUPERPARAMAGNETIC Fe3O4 NANOPARTICLES FOR MFH 
AGENT APPLICATIONS 
 
4.1 Introduction and Motivation 
 Superparamagnetic Fe3O4 (SP-Fe3O4) nanoparticles have been and are being 
widely studied for MFH agent applications due to its officially approved high 
biocompatibility (from FDA, Food and Drug Administration) [1]. Accordingly, 
various technical and engineering approaches, i.e. developing various synthesis 
methods, controlling particle dipole-dipole interaction and particle dispersion status in 




 ion distributions on heating ability 
etc., have been made to improve the AC magnetically-induced heating characteristics 
and the relevant magnetic properties of SP-Fe3O4 nanoparticles for MFH agent 
applications [2-4]. However, SP-Fe3O4 nanoparticles reported so far have critical 
challenges for MFH agent applications, because the magnetic phase (intrinsic 
magnetic property) of the developed SP-Fe3O4 nanoparticles is not well defined and 
has strong dependence on the particle sizes as well as correspondingly wide 
distribution of SLP values (5 ~ 500 W/g) [2-5]. Therefore, systematic studies on the 
magnetic nature and the AC heating characteristics of Fe3O4 nanoparticles accurately 
controlled the particle sizes are essentially required to evaluate the biotechnical 
feasibility of Fe3O4 nanoparticles, particularly SP-Fe3O4 nanoparticles, for MFH agent 
applications. 
 In this study, we investigated the magnetic properties and the AC heating 
characteristics of Fe3O4 nanoparticles with different mean diameters, d, systematically 
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controlled from 4.2 to 22.5 nm to explore what size of Fe3O4 nanoparticles show pure 
superparamagnetic phase and what the AC heating characteristics of the pure 
SP-Fe3O4 nanoparticles are. In order to clearly study the physical relationship between 
magnetic phase of Fe3O4 nanoparticles and SLP characteristics, AC/DC hysteresis, 
out-of-phase (χ") magnetic susceptibility, blocking temperature (TB) and AC 
magnetically-induced heating temperature (TAC,mag) were employed to evaluate the 
magnetic and AC heating nature of Fe3O4 nanoparticles with different particle sizes. 
 Fe3O4 nanoparticles with various particle sizes were synthesized using both the 
conventional HTTD method and seed-mediated growth method [6,7]. For the 
seed-mediated growth method, a 4.2 nm and a 5.8 nm Fe3O4 nanoparticles, which 
were synthesized using the conventional HTTD method, were used as seed particles to 
make 7.9 nm, and 9.8 nm Fe3O4 nanoparticles, respectively. In a similar way, the 7.9 
nm and 9.8 nm Fe3O4 nanoparticles were used as seed particles for the larger Fe3O4 
nanoparticles (d ≥ 11.8 nm). By using the same procedure described above, all the 
Fe3O4 nanoparticles used in this study were synthesized. The synthesized Fe3O4 
nanoparticles were coated with dimercaptosuccinic acid (DMSA) to disperse in the 
water for ferrofluids [8]. 
 The size and its distribution of the Fe3O4 nanoparticles were analyzed by using a 
HR-TEM. The DC magnetic hysteresis of the Fe3O4 nanoparticles was evaluated by 
using a VSM and the magnetic susceptibilities were determined using a PPMS. The 
zero field cooling/field cooling (ZFC/FC) measurement was carried out using a 
MPMS to study the blocking temperature of the Fe3O4 nanoparticles with different 
particle sizes. The TAC,mag and the AC magnetic hysteresis were measured using an 
AC solenoid coil-capacitor system at the fixed fappl of 110 kHz and Happl of 140 Oe. 
All the AC/DC magnetic characteristics and the TAC,mag of the Fe3O4 nanoparticles 
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were investigated in solid states. The SLP of the DMSA coated Fe3O4 nanoparticles 
was evaluated in an agar solution with viscosity controlled at a 3.34 × 10
-3
 Pa (similar 
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4.2 Particle Size and Particle Distribution 
 The size and its distribution of the solid state Fe3O4 nanoparticles were analyzed 
by using a HR-TEM as shown in Figs. 4-1 (a) ~ (f). In addition, the hydrodynamic 
diameter (dH), size distribution, and PDI of the DMSA coated Fe3O4 nanoparticles 
were measured by using a DLS to investigate the dispersion and agglomeration status 
of the DMSA coated Fe3O4 nanoparticles (Table 4-1). The HR-TEM images revealed 
that the sizes of Fe3O4 nanoparticles were well controlled from 4.2 nm to 22.5 nm. 
The DLS results also showed that the DMSA coated Fe3O4 nanoparticles were well 
dispersed in fluids without obvious agglomerations indicating that there is no 
undesirable change in the magnetic as well as the TAC,mag characteristics of the coated 
Fe3O4 nanoparticles [9,10]. 
 
Table 4-1 Mean hydrodynamic diameters (dH), size distributions, and polydispersity 
index (PDI) values of DMSA coated Fe3O4 nanoparticles 
 
Mean diameter of uncoated Fe3O4 
nanoparticles measured by TEM (nm) 
  9.8 14.0   22.5 
Mean hydrodynamic diameter, dH (nm)   23  32   49 
Size distribution (standard deviation (%)) 
± 16 ± 15  ± 15.7 
Polydispersity index (PDI) 0.297 0.311   0.309 
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Figure 4-1 TEM images of Fe3O4 nanoparticles with different mean diameters. (a) 4.2 
nm, (b) 5.8 nm, (c) 9.8 nm, (d) 11.8 nm, (e) 16.5 nm, and (f) 22.5 nm 
CHAPTER 4 PHYSICAL LIMITS OF CURRENT SUPERPARAMAGNETIC Fe3O4 
NANOPARTICLES FOR MFH AGENT APPLICATIONS 
69 
4.3 Dependence of Magnetic Phase on Particle Size 
 Figure 4-2 (a) shows the size dependence of Fe3O4 nanoparticles on the saturation 
magnetization (Ms) and coercivity (Hc). The Fe3O4 nanoparticles with a d = 4.2 nm 
showed the smallest Ms value due to the large number of surface disordered spins and 
a lower magnetic crystalline anisotropy [5]. In addition, the Ms was monotonically 
increased with increasing the particle size and then saturated at a d = 9.8 nm. The 
effects of particle size on the magnetic nature of Fe3O4 nanoparticles can also be well 
understood from the change in Hc as shown in Fig. 4-2 (a). The Fe3O4 nanoparticles 
with a d < 9.8 nm showed almost zero or below 0.3 Oe of Hc indicating that they have 
pure superparamagnetic phase. While, the Fe3O4 nanoparticles with a size of 9.8 < d < 
22.5 nm had a relatively large Hc increased up to 10 Oe apparently demonstrating that 
they have ferrimagnetic phase. However, considering further the relationship between 
Hc and particle size, Fe3O4 nanoparticles with a 9.8 < d < 22.5 nm can be classified 
into two magnetic phases: (1) mixture of superparamagnetic with ferrimagnetic phase 
(mixed phase: 9.8 < d < 16.5 nm), and (2) pure ferrimagnetic phase (FM-Fe3O4 
nanoparticles). In order to precisely clarify the magnetic phases of the Fe3O4 
nanoparticles depending on the particle sizes, the TB was determined from ZFC/FC 
measurement (Fig. 4-2 (b)). The peak in the ZFC curve is associated with mean TB 
and the junction point between ZFC and FC is directly relevant to maximum TB [11]. 
As can be clearly seen in Fig. 4-2 (b), the Fe3O4 nanoparticles with d = 4.2 nm, and d 
= 9.8 nm had well-defined mean TB of 75 K, and 117 K as well as maximum TB of 
210 K, and 240 K, respectively, demonstrating that they are pure SP-Fe3O4 
nanoparticles. While, the Fe3O4 nanoparticles with a d = 22.5 nm showed typical 
FM-Fe3O4 nanoparticles characteristics. However, for the case of Fe3O4 nanoparticles 
with d = 11.8 and d = 16.5 nm, although these Fe3O4 nanoparticles had a mean TB (d = 
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Figure 4-2 (a) Dependence of saturation magnetization and coercivity on the particle 
size of Fe3O4 nanoparticles, and (b) ZFC/FC curves of Fe3O4 nanoparticles (d = 4.2, 9.8, 
11.8, 16.5, and 22.5 nm) 
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11.8 nm) or did not have well-defined mean TB (d = 16.5 nm), their ZFC curves did 
not meet with the FC curves below 300 K indicating that two kinds of magnetic 
phases (superparamagnetic and ferrimagnetic phases) of Fe3O4 nanoparticles exist in 
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4.4 Dependence of AC Magnetically-Induced Heating Characteristics 
on Magnetic Phase and Mechanisms 
 The TAC,mag of the Fe3O4 nanoparticles was measured to investigate the 
dependence of particle size (or magnetic phase) on the SLP and the feasibility of pure 
SP-Fe3O4 to a MFH agent. Figure 4-3 shows the TAC,mag of, (a) solid sate Fe3O4 
nanoparticles and (b) DMSA coated Fe3O4 nanoparticles dispersed in an agar solution, 
measured at the fixed fappl of 110 kHz and the Happl of 140 Oe and the SLPs obtained 
from the DMSA coated Fe3O4 nanoparticles were summarized in Table 4-2. 
 
Table 4-2. SLPs of DMSA coated Fe3O4 with different particle sizes. 
 
 The SLP showed a strong dependence on the particle size. The pure FM-Fe3O4 
nanoparticles showed higher SLPs (> 300 W/g), while the mixed phase of Fe3O4 
nanoparticles had slightly lower SLPs (150 ~ 249 W/g) than pure FM-Fe3O4 
nanoparticles. However, the pure SP-Fe3O4 nanoparticles (d < 9.8 nm) showed very 
low SLPs (< 45 W/g). To elucidate the dependence of SLPs on the magnetic phases of 
Fe3O4 nanoparticles, DC/AC minor hysteresis area (loss), ADC/AAC, and χ" were 
analyzed, because ADC, and χ", which is directly proportional to AAC as well as related 
to AC magnetic softness (magnetic exchange or inverse relationship with magnetic 
anisotropy, Ka), given by Eq. (4-4-1) and (4-4-2) are dominant heating mechanisms 
for pure FM-Fe3O4 nanoparticles, and pure SP-Fe3O4 nanoparticles, respectively 
[12,13]. In addition, the Ptotal given by Eq. (4-4-3) and the PNéel relaxation loss, of the 
Size (nm) 4.2 5.8 7.9 9.8 11.8 14.0 16.5 20.0 22.5 
SLP (W/g) 45 30 28 28 150 201 249 309 322 
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Fe3O4 nanoparticles were experimentally determined to confirm the contribution of 
the PNéel relaxation loss to the Ptotal. Particularly, by considering the physical relationship 
between Eq. (4-4-1) and PNéel relaxation loss, it was clearly understood that the PNéel relaxation 
loss is directly proportional to the AAC as expressed in Eq. (4-4-4). From this physical 
viewpoint, the PNéel relaxation loss was evaluated by AC minor hysteresis measurement at 
the same Happ and fapp used for the TAC,mag measurement. 
 
 
Figure 4-3 AC magnetically-induced heating characteristics of Fe3O4 nanoparticles 
with different particle sizes measured at Happl of 140 Oe and fappl of 110 kHz: (a) 
solid state Fe3O4 nanoparticles and (b) DMSA coated Fe3O4 nanoparticles dispersed 
in an agar solution 
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                                               (4-4-2) 
 





0 applACappltionlossNeelrelaxa HfP  applACapplHf , A AC r/            (4-4-4) 
 
(Cvol: volumetric heat capacity, m: mass of Fe3O4 nanoparticles, Tmax: maximum AC 
heating temperature, M: magnetic moment, μ: permeability (μ0,μr: vacuum and 
relative permeability), and τeff, τN, τB: effective, Néel, and Brown relaxation time). 
 
 Figure 4-4 (a) and (b) show the DC and AC minor hysteresis loops and Table 4-3 
shows the χ", ADC, AAC, Ptotal, PNéel relaxation loss, and contribution of the PNéel relaxation loss 
to the Ptotal of the Fe3O4 nanoparticles with different particle sizes. The pure SP-Fe3O4 
nanoparticles (d < 9.8 nm) showed no ADC but they had a small AAC indicating that 
there is almost zero contribution of ADC to the Ptotal of SP-Fe3O4 nanoparticles. The 
ADC began to appear for the Fe3O4 nanoparticles with a d = 11.8 nm. The ADC was 
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Figure 4-4 Minor hysteresis loops of Fe3O4 nanoparticles: (a) DC minor hysteresis 
loops swept at Happl of ±140 Oe, and (b) AC minor hysteresis loops swept at the 
fixed fappl of 110 kHz with the Happl of ±140 Oe 
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rapidly increased from 15.7 erg/cm
3
 (d = 11.8 nm) to 190.9 erg/cm
3
 (d = 22.5 nm) and  
correspondingly, the Ptotal was increased from 17.9 W/m
3
 to 41.3 W/m
3
 along with the 
reduction in the contribution of PNéel relaxation loss to the Ptotal from 89 % to 47 % clearly 
demonstrating that the higher Ptotal of mixed phase of Fe3O4 nanoparticles (9.8 < d < 
16.5 nm) and pure FM-Fe3O4 nanoparticles compared to the SP-Fe3O4 nanoparticles 
(d < 9.8 nm) is primarily due to the increase of ADC. In contrast, as can be seen in 
Table 4-3, the Ptotal of pure SP-Fe3O4 nanoparticles dominantly contributed by PNéel 
relaxation loss (> 94 %), which is directly proportional to the AAC (or χ") (see Eq (4-4-4)), 
is much smaller than those obtained from mixed phase and pure ferrimagnetic phase 
of Fe3O4 nanoparticles due to the naturally small χ" value of the pure SP-Fe3O4 
nanoparticles. These results indicate that although pure SP-Fe3O4 nanoparticles are 
promising for in-vivo nanomedicine agents such as MRI contrast agent and drug 
delivery agent due to superparamagnetic properties and reasonable particle size for 
efficacious injection, the extremely lower AC heating power (insufficient SLP) is the 
critical physical limit for an MFH agent application for induction of HSP. 
 
Table 4-3. Summaries of calculated and measured physical values (parameters) of Fe3O4 
nanoparticles with different: AC/DC hysteresis area (loss), out-of-phase magnetic 
susceptibility, Ptotal, PNéel, and the contribution of PNéel to the Ptotal in percent. 
Size (nm) 4.2 9.8 11.8 16.5 22.5 
Area of AC Hysteresis (a.u) 33 9.2 25.4 106 258 
Area of DC Hysteresis (erg/cm
3














 6.6 5.5 17.9 31.9 41.3 













 (× 100 (%)) 95 94 89 66 47 
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4.5 Summary 
 It was clearly demonstrated that the Fe3O4 nanoparticles with different mean 
diameters systematically controlled from 4.2 to 22.5 nm have three different magnetic 
phases, and correspondingly different SLP characteristics depending on the particle 
sizes. Among the three magnetic phases of Fe3O4 nanoparticles, the pure SP-Fe3O4 
nanoparticles (d < 9.8 nm) showed a very low SLP (< 45 W/g) because of the 
naturally small AAC (or χ") value and accordingly low PNéel relaxation loss, which only 
contributes to the Ptotal. This would be considered as the most challengeable physical 
limit for the application of pure SP-Fe3O4 nanoparticles to a MFH agent. Therefore, 
intensive studies should be urgently needed to improve the AAC (or χ") of the pure 
SP-Fe3O4 nanoparticles or to develop a new promising SPNPs MFH agent. This can 
be achieved by adjusting magnetic anisotropy energy (or exchange energy) via 
tailoring particle size distribution as well as particle dispersion in fluidics, and adding 
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CHAPTER 5 PHYSICAL STUDIES FOR IMPROVING 
AC MAGNETICALLY-INDUCED HEATING OF SPNPS 
FOR MFH AGENT APPLICATIONS 
 
5.1 Introduction and Motivation 
 As mentioned earlier, MFH using SPNPs has been considered to be an efficacious 
thermal therapy modality due to its biotechnical promises [1-5]. Accordingly, a great 
deal of primary research activities relevant to theoretical and experimental studies 
such as, the development of various kinds of high performance of SPNPs agents, and 
the development of various coating techniques of SPNPs agents for improving 
mono-dispersion status in ferrofluids, has been made and is being intensively carried 
out for real clinical use [6-11]. However, despite the huge biotechnical and scientific 
efforts, current MFH still faces critical challenges: 1) systemic "side effects", 2) low 
AC heat generation ability, and 3) inhomogeneous heating in targeted cells. One of the 
main physical reasons for these technical limitations is that there has been no 
powerful fluidic SPNP agents, which can exhibit exceptionally high SLP and 
sufficiently high enough TAC,mag as well as ultra fast AC heating rate in the 
biologically and physiologically tolerable range of applied magnetic field (Happl ~ < 
190 Oe) and frequency (fappl ~ < 120 kHz). Moreover, a lack of understanding on the 
AC magnetically-induced heating characteristics and mechanisms of SPNPs, i.e. the 
Néel or Brownian relaxation loss power (in a solid state and a fluid state), the physical 
nature of AC heating characteristics such as what physical parameters dominantly 
contribute to the total AC heating power (Ptotal), the Néel relaxation loss power, and 
Brownian relaxation loss power of SPNPs, and the effects of surrounding 
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microenvironment such as, chemical environment, surface chemical status of coated 
nanoparticles, and dispersion status of SPNPs in suspension on the AC heating ability, 
is considerably responsible for the technical limitations of current MFH. Therefore, a 
systematic and intensive study to understand the physical mechanisms and the 
characteristics of AC magnetically-induced heating of SPNPs is urgently needed to 
achieve highly efficient MFH modality. 
 In this chapter, firstly, we explored the physical mechanism of TAC,mag and 
identified what physical parameters would be the most critical to enhance the 
relaxation loss power of SPNPs using MFe2O4 (M = Mg, Ni, and Mn0.5Zn0.5) 
nanoparticles. Secondly, we investigated and analyzed the AC magnetically-induced 
heating characteristics of various viscous ferrofluids with either coated soft ferrite 
(Fe3O4) or hard ferrite (CoFe2O4) SPNPs for interpreting the contribution of Néel 
relaxation loss power, PNéel relaxation loss, or Brown relaxation loss power, PBrown relaxation 
loss, to the total AC heat generation of MFH. Lastly, in order to evaluate the feasibility 
of SPNPs used in this study to a MFH agent, the in-vitro biocompatibility 
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5.2 Physical Mechanism and Crucial Physical Parameters to Enhance 
AC Heat Generation Power of SPNPs 
 In this study, we explored the physical mechanism of ΔTAC,mag and identified 
what physical parameters would be the most critical to enhance the AC 
magnetically-induced heating power of SPNPs using successfully synthesized solid 
state MFe2O4 (M = Mg, Ni, Mn0.5Zn0.5, d = 6 ~ 8 nm) SPNPs for MFH agent 
applications. In order to quantitatively estimate the AC heating characteristics and to 
build up a physical model, which can describe the real contribution of relaxation loss 
power to the Ptotal of SPNPs, intrinsic magnetic properties of SPNPs such as AC 
hysteresis loss behavior, DC (minor) hysteresis behavior, and in-phase (χ´m) or 
out-of-phase (χ˝m) magnetic susceptibility were experimentally measured and 
analyzed. In addition, based on the experimentally analyzed results, some technical 
and engineering approaches, which can improve the χ˝m of SPNPs, were proposed and 
introduced to provide crucial information how to effectively design and develop a new 
promising MFH agent. 
 Superparamagnetic MFe2O4 (M = Mg, Ni, Mn0.5Zn0.5) nanoparticles were 
synthesized by using the conventional HTTD methods. The size and the size 
distribution of the synthesized SPNPs were determined using a HR-TEM. The 
ΔTAC,mag characteristics and the AC hysteresis loss behavior were measured by using 
an AC solenoid coil-capacitor system. The fappl, and the Happl during ΔTAC,mag and AC 
hysteresis loop measurement were fixed at 110 kHz, and 140 Oe, respectively. The 
DC minor hysteresis loop was measured by using a VSM, and a PPMS was employed 
to determine the χ´m and χ˝m of the synthesized SPNPs. The contribution of Prelaxation 
loss to the Ptotal of SPNPs was quantitatively analyzed based on the experimentally 
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Figure 5-1 The particle size and the size distributions of the superparamagnetic 
MgFe2O4, NiFe2O4 and Mn0.5Zn0.5Fe2O4 nanoparticles measured by HR-TEM 
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obtained results including ΔTAC,mag, AC and DC magnetic minor hysteresis loops, and 
magnetic susceptibilities. The cytotoxicity and the cellular uptake of the synthesized 
nanoparticles were investigated by employing methylthiazol tetrazolium bromide test 
(MTT) method using a CCK-kit8 and a TEM using neuronal stem cells isolated from 
human fetal midbrain and human neural cells to evaluate the biocompatibility and to 
investigate the bio-feasibility to MFH agent applications. 
 
5.2.1 Size, size distribution, and TAC,mag of SPNPs 
 HR-TEM images (Fig. 5-1) show the size and the size distribution of the 
MgFe2O4, NiFe2O4, and Mn0.5Zn0.5Fe2O4 nanoparticles. The nanoparticles had d = 6 ~ 
8 nm with a 12.5 % standard deviation. In order to verify the superparamagnetic 
nature of the synthesized nanoparticles, DC minor hysteresis behavior of the 
nanoparticles was investigated at the sweeping field, Happl, of ± 140 Oe at room 
temperature (RT). Figure 5-2 shows the DC minor hysteresis behavior of all the 
nanoparticles. The nanoparticles did not exhibit any DC minor hysteresis loss directly 
indicating that these nanoparticles are superparamagnetic nanoparticles. In order to 
investigate the AC magnetically-induced heating characteristics of all the 
nanoparticles, the ΔTAC,mag was measured at the fixed fappl of 110 kHz and Happl of 140 
Oe. Figures 5-3 show the ΔTAC,mag of all the SPNPs. As can be seen in the results, the 
Mn0.5Zn0.5Fe2O4 SPNPs exhibited the highest ΔTAC,mag and the NiFe2O4 SPNPs had 
the lowest ΔTAC,mag. 
 
5.2.2 Physical mechanism and crucial physical parameters 
 In order to systematically understand the AC heating characteristics and to 
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Figure 5-3 AC magnetically-induced heating temperatures of solid state 




Figure 5-2 DC minor hysteresis loop of superparamagnetic nanoparticles measured 
at a DC Happl of ±140 Oe 
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identify the physical parameters, which can potentially improve the ΔTAC,mag of 
SPNPs, the intrinsic magnetic properties, i.e. χ´m, χ˝m, and AC hysteresis loop 
characteristics of the SPNPs were experimentally investigated. In addition, the 
physical contribution of relaxation loss power, Prelaxation loss, to the Ptotal was calculated 
and analyzed based on the experimentally measured results to explore the physical 
nature of AC heating mechanism in SPNPs. 
 The Prelaxation loss is defined as the AC magnetically-induced heat generation caused 
by either spin relaxation (or rotation), "Néel relaxation", in a core of magnetic 
nanoparticle or magnetomechanical friction force generated among the rotating 
magnetic nanoparticles due to the increase of surrounding temperature and the change 
of (bio)chemical environment, "Brown relaxation". The Prelaxation loss dominantly 
contributes to the AC heating power of SPNPs, because they have no DC minor 
hysteresis loss. In addition, the Prelaxation loss is directly proportional to the χ˝m of SPNPs 
expressed as a function of the Néel relaxation time (τN) or Brown relaxation time (τB) 
(see Eqs. (5-2-1) and (5-2-2)). However, for the solid state SPNPs with d = 6 ~ 8 nm 
considered in this study, it can be assumed that: 1) τN is much faster than τB, 2) τB can 
be negligible due to relatively high packing fraction, and 3) τB can be neglected, 
because it is hard to define the viscosity, η, (τB=3ηVH/kBT, VH: hydrodynamic volume, 
∴τ  τN in Eq. (5-2-1)) [10]. Therefore, the Prelaxation loss of solid state SPNPs can be 













  (1/τ = 1/τB + 1/τN)                              (5-2-1) 
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0 applACapplmtionlossNeelrelaxalossrelaxation HfPP                   (5-2-2) 
 
 In order to find the physical mechanism of AC heating characteristics of SPNPs, 
we explored the physical relationship between the intrinsic AC magnetic properties 
such as, AC hysteresis loss or area (A) and χ˝m, and the AC magnetically-induced 
heating characteristics of SPNSs to identify what physical mechanism is dominant and 
what physical parameters are crucial to significantly improve the AC heating power of 
SPNPs for MFH agent applications. The χ˝m and A are induced by the response of 
magnetic spins (moments) to the externally applied AC magnetic field. Hence, their 
physical relationship can be described and expressed by Eq. (5-2-3) ~ Eq. (5-2-6). 




)(   (BAC,appl: total flux density, (μHAC,appl)).                (5-2-3) 
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   A .                                             (5-2-6) 
 
 In addition, by substituting Eq. (5-2-6) into Eq. (5-2-2), the PNeel relaxation loss can be 
rewritten as Eq. (5-2-7). According to Eq. (5-2-7) and Eq. (5-2-6), it can be clearly 
understood that PNeel relaxation loss of SPNPs under AC magnetic field is the same as the 
AC hysteresis loss power, PAC hysteresis loss. In particular, it is physically confirmed that: 
1) PNeel relaxation loss and PAC hysteresis loss are directly proportional to the A, and 2) the A is 
directly proportional to the χ˝m.  
 
applACappllosshysteresisAClossrelaxationNeel
HfPP ,     A /μr 
(μr: relative permeability).                                          (5-2-7) 
 
 As described in Eq. (5-2-3) ~ Eq. (5-2-7), the PNeel relaxation loss is the main physical 
mechanism responsible for the AC heating power of SPNPs and its contribution to the 
Ptotal of SPNPs can be directly estimated by experimentally evaluating the both χ˝m 
and A. Hence, the χ˝m and the A of all the three SPNPs used in this study were 
measured and compared to confirm the physical relation and the role in characterizing 
the AC heating properties of SPNPs. 
 Figure 5-4 shows the AC magnetic properties of SPNPs including AC magnetic 
hysteresis behavior measured at fappl = 110 kHz and HAC,appl = ± 140 Oe and the AC 
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magnetic susceptibility (χ'm and χ˝m) measured at the activation magnetic field of 10 
Oe under the AC frequency varied from 100 Hz ~ 10 kHz. In addition, Table 5-1 
summarizes the calculated PNeel relaxation loss, Ptotal, PNeel relaxation loss/Ptotal, and magnetic 
anisotropy of all the three SPNPs (Mn0.5Zn0.5Fe2O4, MgFe2O4, and NiFe2O4) based on 
the experimentally measured results. Among the three SPNPs, the Mn0.5Zn0.5Fe2O4 
SPNPs, which showed the largest PNeel relaxation loss and Ptotal with a PNeel relaxation loss/Ptotal 
of 96.5 %, had the largest A (highest AC magnetic softness) and χ˝m. 
 In contrast, the NiFe2O4 SPNPs, which showed the smallest PNeel relaxation loss and 
Ptotal with a PNeel relaxation loss/Ptotal of 93.9 %, had the smallest A (lowest AC magnetic 
softness) and χ˝m. These experimentally and quantitatively analyzed results shown in 
 
 
Figure 5-4 Intrinsic magnetic properties of all the three superparamagnetic 
nanoparticles: (a) AC hysteresis loop, (b) AC hysteresis loop measured at the 
sweeping field of ± 25 Oe with fappl: 110 kHz, (c) in-phase magnetic susceptibility, and 
(d) out-of-phase magnetic susceptibility 
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Fig. 5-4 and Table 5-1 demonstrate that the PNeel relaxation loss dominantly contributes to 
the Ptotal of SPNPs and it is directly proportional to the A (see Eq. (5-2-7)) as well as 
the χ˝m. In particular, these results provide us crucial information that the AC heating  
Table 5-1 Calculation results of the real contributions of PNeel relaxation loss to the Ptotal and 



















MgFe2O4 -0.4 × 10
5
 4.96 × 10
6
 5.1 × 10
6
 97.2 
NiFe2O4 -0.7 × 10
5
 1.40 × 10
6
 1.49 × 10
6
 93.9 
Mn0.5Zn0.5Fe2O4 -0.18 × 10
5
 5.54 × 10
6




ability of SPNPs can be directly estimated by measuring the AC hysteresis behavior or 
the AC hysteresis loss (area) at the same AC magnetic field condition of AC 
magnetically-induced heating, because the χ˝m, which is related to the "Néel 
relaxation time of magnetic spins, τN" (see Eq. (5-2-1)), is directly proportional to the 
A (see Eq. (5-2-6)). In order to more clearly understand the physical relationship 
between the A and the χ˝m as well as their effects on the AC heat generation of SPNPs, 
magnetic anisotropy (K) of the SPNPs and the physical correlation with the A and the 
χ˝m were explored. The main reason for this study is that K is closely relevant to the 
magnetic spin motion (relaxation) or "Néel relaxation time of magnetic spins, τN", and 






N                                                   (5-2-8) 
(τ0: relaxation time constant, V: volume of particle, kB: Boltzmann constant, and T: 
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And, the relationship among the A, χ˝m, and K can be clearly expressed by combining 











 , ∴ A 
K
1
 .                          (5-2-9) 
 
 According to Eq. (5-2-9), it can be physically understood that the A and the χ˝m 
are inversely proportional to the K of SPNPs. As experimentally confirmed in Table 
5-1, the Mn0.5Zn0.5Fe2O4 SPNPs, which showed the largest A, exhibited the lowest K 
value (highest AC magnetic softness), while the NiFe2O4 SPNPs, which showed the 
smallest A, had the highest K (lowest AC magnetic softness). These results indicate 
that the significant enhancement of A (or χ˝m) by controlling the AC magnetic softness 
(K, or magnetic exchange coupling) is the most important physical parameter (or 
approach) to improve the Ptotal (PNeel relaxation loss) of SPNPs for MFH agent applications 
in nanomedicine. The AC magnetic softness of SPNPs such as ferrite SPNPs, MFe2O4 
(M: transition metals) SPNPs, could be enhanced by improving the exchange energy 
(coupling), the AC frequency response, and the τN. The addition of a non-magnetic 
cation to the tetrahedral site or the addition of a magnetic cation, which has a higher 
Bohr magneton than that of iron, to the octahedral site of ferrite SPNPs could be 
introduced and proposed as a critical approach to improve the magnetic exchange 
coupling or to reduce the magnetic anisotropy. In addition, shallow doping of a new 
cation with a faster τ0 such as Cobalt ion or substitution of cation with higher 
magnetic permeability by tetrahedral site of ferrite SPNPs would be proposed to 
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improve the AC frequency response time and spin relaxation time [15]-[18]. 
 
5.2.3 Biocompatibility of SPNPs 
  In addition to the studies on the AC magnetically-induced heating 
characteristics and the physical nature of AC heating mechanism of ferrite SPNPs, in 
order to evaluate the feasibility of SPNPs used in this study to a MFH agent, the 
in-vitro biocompatibility (or cytotoxicity) of the nanoparticles were investigated with 
neuronal stem cells isolated from human fetal midbrain. Figure 5-5 (a) shows the cell 
survival rate of the SPNPs under different nanoparticle concentrations. As can be seen 




Figure 5-5 Studies of in-vitro biocompatibility of the superparamagnetic 
nanoparticles: (a) cell survival rate of all the superparamagnetic nanoparticles with 
neuronal stem cells, and (b) TEM study results of cellular uptake characteristics of 
all the superparamagnetic nanoparticles by human neural cells 
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mid-cytotoxicity) with standard deviations of 8 % ~ 10 % depending on the 
nanoparticle concentrations. The studies on the uptake characteristic of the SPNPs by 
a cell and its cytological change caused by the infused SPNPs were conducted by 
TEM using human neural cells (F3Lacz). In order to induce HSPs in the cells, the 
nanoparticle agents have to be initially absorbed by the cells and located inside the 
cells without side effects such as cell deformation, inflammation and nucleus 
fragmentation. As can be seen in Fig. 5-5 (b), all the SPNPs were successfully uptake 
and located in the cytoplasm of F3Lacz (black arrows) without any side effects. The 
relatively high biocompatibility of all the SPNPs used in this study demonstrated that 
they can be potentially considered to be a MHF agent for local induction of HSPs. 
 
5.2.4 Summary 
 Solid state MFe2O4 (M = Mg, Ni, and Mn0.5Zn0.5) SPNPs were used to explore 
the physical mechanisms of AC magnetically-induced heating and identify what 
physical parameters would be the most critical to enhance the AC heating power for 
MFH agent applications. According to the experimental results, the PNeel relaxation loss (or 
PAC hysteresis loss) dominantly contributed to the Ptotal of SPNPs. Moreover, it was 
physically demonstrated that the A (or χ˝m), directly relevant to the AC magnetic 
softness, are the most crucial physical parameters to enhance the PNeel relaxation loss. 
Controlling the magnetic anisotropy, the exchange coupling (energy), and the 
relaxation time constant of SPNPs by tailoring the magnetic and structural properties 
of SPNPs would be the most efficient technical approaches to significantly improve 
the physical parameters for their MFH agent applications. 
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5.3 Physical Contribution of Néel and Brown Relaxation loss Power 
to AC Heat Generation of MFH Agents 
 In this study, the AC magnetically-induced heating characteristics of various 
viscous ferrofluids with coated ferrite SPNPs were investigated to evaluate and to 
interpret the physical contribution of PNéel relaxation loss and PBrown relaxation loss to the total 
AC heat generation and the SLP of ferrofluids for MFH agent applications. In order to 
apparently differentiate the relaxation mode of SPNPs in a fluidic state under AC 
magnetic field, two magnetically distinct SPNPs, soft (lower magnetic anisotropy or 
larger exchange energy, Fe3O4) and hard (higher magnetic anisotropy or smaller 
exchange energy, CoFe2O4) ferrite nanoparticles were considered. In addition, to 
exclude the effects of nanoparticle size & size distribution on the relaxation mode of 
heating power, either Néel relaxation loss power or Brown relaxation loss power, and 
to physically assume that the AC heat generation of synthesized solid state 
nanoparticles is dominated by the "Néel relaxation loss power" [9,10] the solid state 
soft Fe3O4 and hard CoFe2O4 ferrite nanoparticles were prepared and controlled to 
have a similar mean particle size below 8 nm and pure superparamagnetic phase. The 
synthesized two solid state SPNPs were coated with amorphous silica for making 
ferrofluids (noted by "Fe-ferrofluid", and "Co-ferrofluid", respectively) and then the 
viscosity, η, of the two ferrofluids was varied from 1 × 10-3 Pa·s (similar to viscosity 
of water) to 4 × 10
-3
 Pa·s (similar to viscosity of cytoplasm) to explore the effects of 
surrounding viscosity on the AC magnetically-induced heating characteristics (such as 
total AC heating power, Ptotal, relaxation loss power, Prelaxation loss power, and SLP), 
particularly Prelaxation loss power behavior, of ferrofluids under AC magnetic field. The 
applied AC frequency (fappl) and the magnetic field (Happl) during heating were fixed 
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at fappl = 111 kHz and Happl = 140 Oe, which are in the biologically safe and 
physiologically tolerable range. Moreover, the externally applied AC total power or 
energy, fappl·Happl, during heating was controlled to be placed in the between 
magnetostatic energy (or magnetic energy barrier) of Fe3O4 and CoFe2O4 SPNPs  
  
5.3.1 Size, size distribution, and magnetic property of nanoparticles 
 The particle core size (or mean particle size, d) and its distribution of the two 
synthesized solid state nanoparticles were first confirmed by analyzing the HR-TEM 
 
 
Figure 5-6 The mean particle size and size distribution of synthesized solid state 
(a) CoFe2O4 and (b) Fe3O4 nanoparticles analyzed by HR-TEM 
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images, because the relaxation loss of nanoparticles under AC magnetic field, either 
Néel or Brown relaxation loss, is strongly dependent on the particle core size. Figures 
5-6 (a) and (b) show the TEM images of CoFe2O4 and Fe3O4 nanoparticles. As can be 
seen in Figs 5-6 (a) and (b), the nanoparticles had a similar small d value and a narrow 
size distribution. The CoFe2O4 nanoparticles had d = 6.1 nm with a 16.3 % of 
standard deviation, and the Fe3O4 nanoparticles had d = 5.8 nm with a 15.5 % of 
standard deviation. This result indicates that the effects of particle core size and its 
distribution on the Néel and Brown relaxation loss can be negligible. 
 In order to investigate the magnetic phase of the two synthesized nanoparticles, 
the DC magnetic minor hysteresis loop was measured at the sweeping, Happl, of ± 140 
Oe, which is similar to the amplitude of AC magnetic field in AC 
magnetically-induced heating. As shown in Figs. 5-7 (a) and (b), the CoFe2O4 and 
Fe3O4 nanoparticles did not have any DC minor hysteresis loss clearly indicating that 





Figure 5-7 The DC minor hysteresis loop of (a) CoFe2O4 and (b) Fe3O4 nanoparticles 
measured at the sweeping field, Happl of ±140 Oe 
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5.3.2 Coating and dispersion statuses of silica coated SPNPs in fluids 
 The solid state CoFe2O4 and Fe3O4 SPNPs were coated with silica to investigate 
the cellular uptake behavior and the AC magnetically-induced heating characteristics 
in ferrofluids. The coating conditions and the dispersion status of the silica coated two 
SPNPs in fluids, Fe-ferrofluid and Co-ferrofluid, were chemically analyzed and 
compared. Figures 5-8 (a) and (b) show the dH, the PDI value, and the surface charge 
of the two silica coated SPNP ferrofluids. As can be seen in Figs. 5-8 (a) and (b), the 
Co-ferrofluid and Fe-ferrofluid had a similar dH value with a narrow size distribution 
(~ 37 nm ± 13.5 %), a similar low PDI value (0.298 ~ 0.302), and a similar 
Z-potential (- 6.62 mV ~ - 7.74 mV) indicating that the two silica coated SPNPs in the 
two ferrofluids are uniformly coated and also well dispersed in aqueous fluids with 
minimal aggregation. Furthermore, the similar small dH values, the similar narrow 
size distribution, and the similar well dispersion status (lower PDI values) of the two 
ferrofluids imply that the two silica coated SPNPs dispersed in the two ferrofluids 
 
 
Figure 5-8 The hydrodynamic diameter (dH), the Z-potential, and the poly dispersity 
index (PDI) of silica coated (a) CoFe2O4 and (b) Fe3O4 SPNPs dispersed in fluids 
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have similar particle-particle dipole interaction leading to a physical assumption that 
there is negligibly small particle dipole interaction in the two ferrofluids and thus 
there is no externally changed relaxation loss mode caused by particle-particle dipole 
interaction. It is well known that the existence of strong particle dipole interaction 
among the coated SPNPs can severely affect the two relaxation loss modes in 
ferrofluidic solutions [19 - 21]. 
 
5.3.3 Biocompatibility of ferrofluids 




Figure 5-9 TEM study results of retinal ganglion cells (RGCs) before and after 
treating by ferrofluids: (a) control RGCs, (b) RGCs treated by silica coated CoFe2O4 
SPNPs ferrofluid, and (c) RGCs treated by silica coated Fe3O4 SPNPs ferrofluid 
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characteristics of ferrofluids on the viscosity, the cellular uptake behavior, the 
dispersion status, and the cytological studies of the cells before and after treating by 
Fe- and Co-ferrofluids were carried out by TEM analysis using RCGs to explore the 
bio-feasibility to a MFH agent (intracellular hyperthermia agent) and to understand 
the AC heating behavior of the two ferrofluids in a cellular level. As shown in Figs. 
5-9 (b) and (c), the silica coated CoFe2O4 and Fe3O4 SPNPs from ferrofluids were 
well absorbed by RGCs and located in the cytoplasm (red arrows) without any 
obvious "side effects" such as cell deformation, inflammation, and nuclei 
fragmentation. The high bio-feasibility and the good enough cell uptake properties of 
Co- and Fe-ferrofluids are manly thought to be due to the stable coating conditions, i.e. 
thin coating thickness, and high uniformity of coating thickness, the well controlled 
dispersion status, and hydrophilic as well as charged surface of coated SPNPs in 
ferrofluids. In particular, the experimental results shown in Fig. 5-8 combining with 
Fig. 5-9 provide us crucial information that the controlling of surface chemistry as 
well as dispersion status of nanoparticle fluidic agents should be considered to be one 
of the most important factors in estimating the performance of ferrofluid for an 
intercellular MFH agent, because it is closely related to the biocompatibility and the 
cellular uptake behavior along with AC heating behavior 
  
5.3.4 Dependence of Néel and Brown relaxation loss power of ferrofluids 
on viscosity 
 After confirming and comparing the particle size, the size distribution, and the 
surface chemistry as well as the dispersion status of the two ferrofluids, the AC 
magnetically-induced heating characteristics were investigated. In order to explore the 
effects of surrounding viscosity on the PNéel relaxation loss and the PBrown relaxation loss and 
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also to study their physical contribution to the Ptotal and the AC heating characteristics, 
various viscous (similar to water, blood and cytoplasm’s viscosities) ferrofluids (1 
mL) with a 20 mg of dispersed silica coated CoFe2O4 and Fe3O4 SPNPs were 
prepared. As shown in Fig. 5-11 (a), the AC magnetically-induced heating temperature 
rise and its characteristics were measured in an agar solution state (or ferrofluid) at the 
fixed fappl = 111 kHz and Happl = 140 Oe. The SLP, and the Ptotal were determined from 












                                        (5-3-1) 
 
maxTmCP NPvtotal                                                 (5-3-2) 
(CVi: volumetric heat capacity of each component (i) in the system, mi: mass of each 
component in the system, 
NPm : mass of nanoparticle, T  and t : 63 % change in 
temperature at maximum temperature (Tmax) and the corresponding change in time) 
  
 Figures 5-10 (b) and (c) show the dependence of ΔTAC,mag and the temperature 
rise behavior of Co- and Fe-ferrofluids on the surrounding viscosity. It was 
interestingly found that the ΔTAC,mag and the temperature rise characteristics of 
Co-ferrofluid were severely influenced by the surrounding viscosity. The 
Co-ferrofluid showed the higher ΔTAC,mag, Ptotal, and SLP (see Figs. 5-11 (a) and (b)) 
than those of Fe-ferrofluid in the low viscous fluidic solution (same as the viscosity of 
water) because of the "Brown relaxation loss" dominated heating power of 
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Figure 5-10 (a) The inductance-capacitance (L-C) controlled AC magnetically-induced 
heating system used for measuring AC heating of Co- and Fe-ferrofluids with different 
viscosities. Figure (b), and (c) show the dependence of surrounding viscosity of 
Co-ferrofluid, and Fe-ferrofluid on the AC magnetically-induced heating temperature 
rise characteristics. The viscosity of two ferrofluids was varied from 1 × 10
-3
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Co-ferrofluids caused by the higher magnetic anisotropy of CoFe2O4 ferrite 
nanoparticles [22,23]. However, compared to Fe-ferrofluid, it was obviously found 
that the ΔTAC,mag, the Ptotal, and the SLP values of Co-ferrofluid were severely 
degraded with increasing the surrounding viscosity and then eventually exhibited 
smaller values than those of Fe-ferrofluid at the viscosity of 4 × 10
-3
 Pa·s, which is the 
similar viscosity to that of blood and cytoplasm. The physically considerable reason 
responsible for the severe reduction of AC heating ability of Co-ferrofluid depending 
on the surrounding viscosity can be elucidated that the higher viscosity makes "Brown 
relaxation time", τB, (τB=3ηVH/kBT, VH: hydrodynamic volume of particles, η: 
viscosity of fluid) longer and thus directly resulting in degrading the contribution of 
PBrown relaxation loss to the Ptotal of Co-ferrofluid under AC magnetic field. In other words, 
this physical explanation can be understood by the fact that the applied AC magnetic 
field controlled at the biologically safe and physiologically tolerable range of fappl = 
111 kHz and Happl = 140 Oe is not sufficient enough to overcome the interfacial 
friction force formed between the silica coated CoFe2O4 SPNPs and the surrounding 
fluidic solutions with higher viscosity values [24]. Hence, the rotational mobility 
(Brown relaxation) of silica coated CoFe2O4 SPNPs in ferrofluid would be interrupted 
by the higher viscosity leading to the drastic AC heating degradation including severe 
reduction of ΔTAC,mag, Ptotal, and SLP, because the PBrown relaxation loss is dominant heating 
mechanism in Co-ferrofluid. The empirically confirmed dependence of AC heating 
characteristics of Co-ferrofluid shown in both Fig. 5-10 and Fig. 5-11 provides us 
physically crucial information that although "Brown relaxation loss power" dominated 
solid state SPNPs agents are paid considerable attentions to be expected for achieving 
highly efficient AC hearing power [9,25,26], the ferrofluid made from the SPNPs 
cannot be considered for an intercellular MFH agent. The main reason is that the cell 
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(cytoplasm) viscosity in an in-vivo or an intercellular state would severely cause to 
degrade the PBrown relaxation loss of SPNPs directly resulting in the dramatic reduction of 
ΔTAC,mag and SLP. 
 In contrast to Co-ferrofluid, as shown in Fig. 5-10 (c) and Fig. 5-11, the ΔTAC,mag, 
the SLP, and the Ptotal of Fe-ferrofluid were independent on the surrounding viscosity 
in the fluidic solutions. Even though there was very slight reduction of SLP (decrease 
 
 
Figure 5-11 The dependence of viscosity on the (a) specific loss power, and (b) total AC 
heating power in AC magnetically-induced heating characteristics of Co- and 
Fe-ferrofluids 
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in AC heating increasing rate, see Fig. 5-11 (a)) due to the increased heat capacity 
caused by the higher surrounding viscosity [27], the AC heating behavior and the 
temperature rise characteristics of Fe-ferrofluid didn't have any physical dependence 
on the variation of surrounding viscosity. These results imply that the ferrofluid made 
from the "Néel relaxation loss power" dominated soft SPNPs will be better for an 
intercelluar MFH agent, because its AC heating characteristics are independent on the 
biochemical environments. Furthermore, from these results, we can speculate that 
developing a superparamagnetic ferrofluid with significantly enhanced PNéel relaxation loss 
rather than PBrown relaxation loss would be the best technical approach to achieve a high 
efficient intercellular MFH modality for local induction of HSPs. 
 
5.3.5 Summary 
 The AC magnetically-induced heating characteristics of various viscous soft- and 
hard-ferrite SPNPs ferrofluids with similar mean particle size & size distribution were 
investigated to study the physical behavior of PNéel relaxation loss and PBrown relaxation loss and 
to understand the contribution to the Ptotal and the SLP of ferrofluids for MFH 
(intracellular hyperthermia) agent applications. It was empirically found that the 
PBrown relaxation loss was severely affected by the surrounding viscosity and its 
contribution to the Ptotal and the SLP was drastically degraded with increasing the 
viscosity up to 4 × 10
-3
 Pa·s (similar to viscosity of cytoplasm or intracellular 
environment). Whereas, the contribution of PNéel relaxation loss to the Ptotal and the SLP 
was independent to the variation of surrounding viscosity of ferrofluids. These 
experimentally and physically analyzed results strongly support the physical fact that 
the effectiveness of MFH can be optimized by enhancing the PNéel relaxation loss rather 
than the PBrown relaxation loss of SPNP agents in ferrofluids. 
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CHAPTER 6 MnxZn1-xFe2O4 SPNPs FOR MFH AGENT 
APPLICATIONS 
6.1 Introduction 
 The ternary phase of superparamagnetic ferrite nanoparticles, MFe2O4 (M = Fe, 
Co, Ni, and Mg), with a mean diameter below 10 nm have been widely studied for 
MFH agent applications. However, despite their promising chemical, physiological, 
biotechnical, and physical properties suitable for MFH agent applications
 
[1-3], an 
insufficient ΔTac,mag and low SLP at the physiologically tolerable range of frequencies 
and magnetic fields are still revealed as the technical challenges to be overcome for a 
real MFH [4,5, and chapter 4 and5]. 
 In this thesis, the quarterly phase of manganese-zinc ferrite (MnxZn1-xFe2O4) was 
chosen to be a potential material for a MFH agent to induce HSPs. The main 
biological and physical reason is that 1) both Mn and Zn are high bio-compatible 
elements (essential trace nutrients – improvement of immunity and metabolism of 
RNZ and DNA), 2) it is one of the softest (or the highest permeability) ferrite 
materials, and 3) it has a good electrical field absorption and a large power loss (50 ~ 
200 W/m
3
) at a low frequency (~100 kHz) which is due to its low electrical resistivity 
(0.02 ~ 20 Ωm) [6,7]. Furthermore, its magnetic properties, i.e. saturation 
magnetization, Ms, and magnetic susceptibility (χm = χ´m + iχ˝m, particularly out of 
phase susceptibility, χ˝m), which are directly relevant to the AC magnetically-induced 





 cations in the MnxZn1-xFe2O4 ferrites [6,8,9]. However, all of the 
works relevant to the MnxZn1-xFe2O4 ferrites done so far were entirely focused on 
magnetoelectronics device applications such as micro antenna, deflection yokes, 
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transformer cores, and switched-mode power supplies [10]. There have been no 
systematic studies on the magnetic properties, AC magnetically-induced heating 
characteristics, and the biocompatibility of MnxZn1-xFe2O4 SPNPs for MFH agent 
applications until now. 




 cations concentration on 
the magnetic properties and the AC magnetically-induced heating characteristics of 
uncoated solid state MnxZn1-xFe2O4 (x = 0.2 ~ 0.8) SPNPs to explore its feasibility as 
a MFH agent. The physical correlation between the magnetic properties of 





cations (i.e. χ˝m, AC magnetic coercivity relevant to the Néel relation time, Ms,) and 
the AC magnetically-induced heating characteristics (ΔTAC,mag, SLP, and power loss 
mechanism) were systematically investigated at different Happl and fappl. In addition, 
the cell viability of solid state MnxZn1-xFe2O4 SPNPs with different Mn
2+
 cation 
concentrations were quantitatively analyzed to evaluate the biocompatibility for MFH 
agent applications. 
 The spinel ferrite MnxZn1-xFe2O4 nanoparticles with different Mn
2+
 cation 
concentration were synthesized using the modified HTTD method, where the 1
st
 




 heat treatment time were changed from the 
conventional HTTD method [chapter 3]. The Mn
2+
 cation concentration of 
MnxZn1-xFe2O4 nanoparticles was systematically controlled from x = 0.2 to 0.8 during 
the synthesis. The crystal structure, the particle size, and the distribution of 
MnxZn1-xFe2O4 nanoparticles were analyzed by using a Cu-kα radiated XRD and a 
HR-TEM. The ΔTAC,mag characteristics and the AC magnetic hysteresis (A) of the 
solid state MnxZn1-xFe2O4 nanoparticles were measured by using an AC solenoid coil 
– capacitor (AC magnetic field generation) system. The fappl and the Happl were varied 
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form 30 kHz to 210 kHz and from 60 Oe to 140 Oe, respectively. The DC magnetic 
properties of the solid state MnxZn1-xFe2O4 nanoparticles were analyzed by using a 
VSM and the χ˝m was measured by using a PPMS. The zero field cooling/field cooling 
(ZFC/FC) measurement was carried out to characterize the dependence of temperature 
on the magnetic properties of MnxZn1-xFe2O4 nanoparticles using a MPMS. The cell 
viability was quantitatively analyzed by employing the CCK 8 assay using neuronal 
stem cells (NSCs) isolated from human fetal midbrain and retinal ganglion cells 
(RGCs). The concentration of MnxZn1-xFe2O4 nanoparticles for cell viability test was 
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6.2 Crystal Structure and Particle Size 
 Prior to studying the magnetic properties and the ΔTAC,mag characteristics, the 
crystal structure, the particle size and the distribution of synthesized MnxZn1-xFe2O4 
nanoparticles were first investigated. As can be seen in Figs. 6-1 (a) ~ (c), the 
synthesized (uncoated solid state) MnxZn1-xFe2O4 nanoparticles had a mean particle 
size of 5.7 nm ~ 6 nm with a 12 % standard deviation and they were well segregated 
with a round shape. In addition, the synthesized MnxZn1-xFe2O4 nanoparticles showed 
a single phase cubic spinel ferrite structure and did not exhibit any undesirable 
 
 
Figure 6-1 TEM images and XRD patterns of synthesized superparamagnetic 
MnxZn1-xFe2O4 nanoparticles with different Mn composition: (a) x = 0.33, (b) x = 
0.5, (c) x = 0.67 and (d) XRD patterns 
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crystalline phases (Fig. 6 (d)). The well controlled structural and chemical stabilities 
of synthesized MnxZn1-xFe2O4 nanoparticles demonstrate that they can be considered 
to be a MFH agent because they are expected to minimize the biochemical reaction 
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 on Magnetic 
and AC Heating Characteristics 




 concentration on saturation magnetization 
 Figures 6-2 and 6-3 (a) show the hysteresis loops of MnxZn1-xFe2O4 nanoparticles 
measured under an externally applied field of Happl = ± 80 Oe (minor loop, Fig. 6-2) 
and Happl = ± 10 kOe (major loop, Fig. 6-3 (a)) at room temperature. As can be seen in 
Fig. 6-2, all of the MnxZn1-xFe2O4 nanoparticles showed no minor hysteresis loss, 
depending on the Mn
2+
 cation concentration, indicating that they have a 
 
 
Figure 6-2 Minor magnetic hysteresis loops of MnxZn1-xFe2O4 SPNPs with different 
Mn-Zn concentration changed from x = 0.2 to x = 0.8 
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superparamagnetic phase at room temperature. As shown in Fig. 6-3 (a), the Ms had a 




 cations concentration. Particularly, the 
Mn0.5Zn0.5Fe2O4 nanoparticle had the highest Ms value of a 47 emu/g. The increase of 
 
 
Figure 6-3 (a) Major magnetic hysteresis loops and (b) Ms values of MnxZn1-xFe2O4 
SPNPs with different Mn-Zn concentration changed from x = 0.2 to x = 0.8, and (c) 
Magnetic spin alignment diagram (yellow arrow: magnetic moment) 
CHAPTER 6 MnxZn1-xFe2O4 SPNPs FOR MFH AGENT APPLICATIONS 
114 
Ms by increasing the Zn
2+
 cation concentration up to x = 0.5 (Mn0.5Zn0.5) is thought to 
be due to the increase of magnetic moment of the unit cell up to 7.5 μB (μB: Bohr 









 ions on the A-site (Tetrahedral site). However, increasing the 
Zn
2+
 cation concentration above x = 0.5 was found to decrease the Ms. This decrease 





on the B-site (Octahedral site) (Fig. 6-3 (b)) [6,11]. 
 




 concentration on AC magnetically-induced 
heating characteristics and AC magnetic properties 
 Figure 6-4 shows the dependence of Mn
2+
 concentration on the ΔTac,mag of 
uncoated solid state MnxZn1-xFe2O4 SPNPs. As can be seen in Fig. 6-4 (a), it was 
clearly observed that the ΔTAC,mag measured at a constant Happl = 80 Oe, fappl = 210 
kHz had a strong dependence on the Mn
2+
 cation concentration. The ΔTac,mag of the 
solid state MnxZn1-xFe2O4 SPNPs was increased by increasing the Mn
2+
 concentration 
and reached a maximum ΔTAC,mag = 39 ℃ at the composition of Mn0.5Zn0.5Fe2O4. A 
further increase of Mn
2+
 concentration, x > 0.5, led to a severe reduction of ΔTAC,mag. 
The physical dependence of fappl and Happl on the ΔTAC,mag is shown in Fig. 6-4 (b) and 
(c). It was clearly demonstrated that the ΔTAC,mag is linearly proportional to the fappl 
and squarely proportional to the Happl. These results strongly imply that the physical 
nature of AC magnetically-induced heating of MnxZn1-xFe2O4 SPNPs is dominantly 
related to the Prelaxation loss as described in Eqs. (5-2-1) and (5-2-2). Furthermore, from 
this point of view, the highest ΔTAC,mag value obtained from the Mn0.5Zn0.5Fe2O4 







, Fig. 6-5 (a)), which resulted from its softest magnetic property (or the 
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highest magnetic permeability) as well as its largest exchange energy induced by the 
half portion of Mn
2+
 cations replaced by the Zn
2+
 cations on the A-site. 
 The AC magnetic hysteresis loops of MnxZn1-xFe2O4 SPNPs measured at Happl = 
 
 
Figure 6-4 (a) Dependence of Mn
2+
 concentration on the AC magnetically-induced 
heating temperature measured at the fixed Happl = 80 Oe and fappl = 210 kHz, and 
Dependence of applied (b) magnetic field and (c) frequency on the AC 
magnetically-induced heating temperature of MnxZn1-xFe2O4 SPNPs 
CHAPTER 6 MnxZn1-xFe2O4 SPNPs FOR MFH AGENT APPLICATIONS 
116 
± 80 Oe and fappl = 210 kHz is shown in Fig. 6-5 (b). The Mn0.5Zn0.5Fe2O4 SPNP 
exhibited the largest AC magnetic hysteresis area, A, among the MnxZn1-xFe2O4 
SPNPs indicating that it has the lowest AC magnetic anisotropy resulting in the fastest 
Néel relaxation time (τN) (or the highest χ˝m described in Eq. (5-2-6) and shown in Fig. 
6-5 (a)). This experimental result provides strong physical evidence that the highest 
ΔTAC,mag of MnxZn1-xFe2O4 SPNP (x = 0.5) is related directly to the well-controlled 
highest χ˝m. Furthermore, this indicates that controlling the AC magnetic softness of 
SPNPs, which is directly relevant to the Néel relaxation behavior, is the most crucial 
factor in determining the ΔTac,mag characteristics. In order to further clarify the 
 
 
Figure 6-5 Measured (a) out-of-phase magnetic susceptibilities and (b) AC magnetic 
hysteresis loops of MnxZn1-xFe2O4 SPNPs 
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physical mechanism of ΔTAC,mag of MnxZn1-xFe2O4 SPNPs, the contribution of 
Prelaxation loss to the total power heat generation, Ptotal, was numerically compared by 
calculating both Ptotal and Prelaxation loss from the experimentally obtained ΔTAC,mag, χ˝m 
(at fappl = 210 kHz), mass, and the volumetric heat capacity values of MnxZn1-xFe2O4 
SPNPs. As can be seen in Fig. 6-6, more than 80 or 90 % of Prelaxation loss contributed to 
the Ptotal of MnxZn1-xFe2O4 SPNPs verifying that the Prelaxation loss, particularly the Néel 
relaxation power loss is dominant for the ΔTAC,mag of MnxZn1-xFe2O4 SPNPs. To 
consider the SPNPs for a real MFH agent without systemic side effect, the SPNPs 
should generate a higher ΔTAC,mag both in a short heat up time and with a mass as low 
as possible. These characteristics can be evaluated by the SLP shown in Fig. 6-6 [12]. 
In this study, the SLP was obtained from the solid state SPNPs (only the temperature 
rising rate (ΔT/Δt) and the mass (mg) were considered from Eq. (5-3-1)) in order to 
roughly confirm the AC heating generation ability of the uncoated solid state 
MnxZn1-xFe2O4 SPNPs, and to compare to other uncoated solid state SPNPs (Fe3O4, 
 
 
Figure 6-6 Néel relaxation loss power, total heat generation power, and SLP (measured 
in solid state) of MnxZn1-xFe2O4 SPNPs  
uncoated, solid state 
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CoFe2O4 and NiFe2O4 SPNPs). As can be seen in Fig. 6-6, the Mn0.5Zn0.5Fe2O4 SPNP 
showed the largest SLP value of 138.4 W/g (in solid state) due to the fastest 
temperature rising rate (ΔT/Δt) caused by the highest χ˝m value among the 
MnxZn1-xFe2O4 SPNPs. This value is considered to be much higher than those 
obtained from the conventional ternary phase solid state SPNPs at the same AC 
magnetic field condition, e.g. Fe3O4 (27.3 W/g), CoFe2O4 (56.1 W/g), and NiFe2O4 
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6.4 Cell Viability of Solid State MnxZn1-xFe2O4 SPNPs 
 The cell viability of uncoated solid state MnxZn1-xFe2O4 SPNPs (x=0.3, 0.5, 0.67) 
and Fe3O4 SPNPs with different concentrations was quantitatively estimated by the 
CFK-8 assay using neuronal stem cells (NSCs) and retinal ganglion cells (RGCs) to 
explore the feasibility to a MFH agent particularly for induction of HSPs. Figure 6-7 
 
 
Figure 6-7 Cell viability of (a) MnxZn1-xFe2O4 SPNPs (x = 0.33, 0.5, and 0.67) with 
neuronal stem cells isolated from human fetal midbrain, and (b) Mn0.5Zn0.5Fe2O4 and 
Fe3O4 SPNPs with retinal ganglion cells  
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shows the cell survival rate of SPNPs treated (a) NSCs, and (b) RGCs, respectively. It 
was clearly confirmed that the cell survival rate of MnxZn1-xFe2O4 SPNPs depends on 
the concentration of nanoparticles in the cell culture media as well as the Mn
2+
 cation 
concentration. All the MnxZn1-xFe2O4 SPNPs showed mid-cytotoxicity (75 % ~ 85 %) 
or non-cytotoxicity (> 85 %). In particular, the Mn0.5Zn0.5Fe2O4 SPNP had the highest 
cell survival rate of around 90 % ~ 80 % ± 8 % (10 % of standard deviation) even at a 
higher nanoparticle concentration. The higher cell survival rate of Mn0.5Zn0.5Fe2O4 
SPNP is thought to be due to the chemically stable phase of Mn0.5Zn0.5Fe2O4 [14], 
which is expected to induce less stress on the cells and the large portion of Mn
2+
 
















CHAPTER 6 MnxZn1-xFe2O4 SPNPs FOR MFH AGENT APPLICATIONS 
121 
6.5 Summary 
 In summary, it was demonstrated that the ΔTAC,mag and the magnetic properties of 
uncoated solid state MnxZn1-xFe2O4 SPNPs had a strong dependence on the Mn
2+
 
cation concentration. Among the MnxZn1-xFe2O4 SPNPs, the Mn0.5Zn0.5Fe2O4 SPNP 
showed the highest ΔTAC,mag, SLP, and biocompatibility, which make it suitable for 
MFH agent applications. The higher χ˝m (and largest A) value directly relevant to the 
Néel relaxation time (or AC magnetic softness) and the higher chemical stability 
systematically controlled by the replacement of Mn
2+
 cations by the Zn
2+
 cations on 
the A-site (tetrahedral site) are the primary physical reason for the biotechnical 
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CHAPTER 7 LOCAL INDUCTION OF HSPS 72 USING 




 In this study, we first present the feasibility of magnetically-engineered 
superparamagnetic Mn0.5Zn0.5Fe2O4 nanoparticles (EMZF SPNPs) to a MFH agent to 
induce HSPs 72 for “ocular neuroprotection” modality. The magnetic, structural, and 
AC magnetically-induced heating characteristics of uncoated and silica or PEG coated 
EMZF SPNPs were explored and compared to Fe3O4 and conventional 
Mn0.5Zn0.5Fe2O4 (using the conventional HTTD method) SPNPs. The AC heating 
characteristics including TAC,mag, SLP, and temperature rise behavior of all the SPNPs 
were evaluated both in a solid state and in a fluid state. In order to investigate the 
physical nature of the improved AC heating characteristics and to confirm the 
superparamagnetic behavior of EMZF SPNPs, the DC/AC magnetic hysteresis 
behavior and the AC response relevant to χ˝m were analyzed at the different ambient 
conditions. The biocompatibility of the uncoated and coated EMZF SPNPs was 
studied in an in-vitro environment by investigating the cell viability, the cell 
penetration, the cell deformation and the cell apoptosis using rat RGCs. 
 Next, we employed MFH using EMZF SPNPs as a new nano-biotechnical 
approach to effectively control the local induction of HSPs 72 and to minimize the 
death rate of healthy cells during the induction of HSPs 72 in RGCs. In order to 
identify the induction of HSPs 72 and to study the induction behavior at the 
intercellular level, the RGSs incubated with three different SPNPs@PEG (500 μg/mL) 
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were collected in a microcentrifuge tube and centrifuged to form a cell pellet. The 
microcentrifuge tube containing the RGCs pellet was immersed in a hot water bath to 
make the temperature of RGCs with SPNPs@PEG keep in the range of 36 ℃ ~ 
37 ℃. As shown in Fig. 7-1, the microcentrifuge tube with an optical thermometer 
(OT, thermal sensor tip) inserted in the RGCs was placed at the center of AC coil to 
apply AC magnetic field. The increasing rate of AC heating stress (AC heating 
characteristic) and the duty cycle of AC heating stress of the SPNPs@PEG in RGCs 
were systematically controlled to improve the efficiency of HSPs 72 induction by 
changing the applied AC magnetic field, Happl, at the fixed applied frequency, fappl, in 







[1]. Particularly, to exclude the induction of HSPs undesirably generated by the 
inaccurately controlled AC heating temperature the saturated AC 
magnetically-induced heating temperature (TAC,mag) was constantly kept at a typical 
HSPs induction temperature of 40.5 ℃ ± 0.5 ℃ [2]. After 24 hours, the induced 
HSPs 72 in the RGCs were confirmed by staining the cells with Anti-HSPs 72 
(primary antibody) and FITC (Fluorescein isothiocyanate, secondary antibody), for 
HSPs 72, and DAPI (4’, 6-diamino-2-phenylindole), for nucleus. 
 Lastly, a new infusion technique, which injects the SPNP agents and transports 
them to the surface of retina, is introduced in this study. The uncoated and coated 
EMZF SPNPs were injected into the rat eyeball and diffused them through the 
vitreous body to the surface of retina. The distribution status of injected EMZF SPNPs 
and the cell apoptosis (or deformation) at the retina surface caused by the injected 
EMZF SPNPs were investigated to evaluate the applicability of MFH in glaucoma 
clinics. 
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Figure 7-1 The specially designed AC magnetically-induced heating system used for 
measuring the AC heating of SPNPs in RGCs 
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7.2 Magnetic Properties and AC Heating Characteristics 
7.2.1 Magnetic and AC heating properties of solid state SPNPs 
 Figures 7-2 (a) and (b) show the TEM images of uncoated solid state EMZF 
nanoparticles. As can be seen in Figs. 7-2 (a) and (b), the uncoated EMZF 
nanoparticles have a mean particle size of 5.5 nm with 12.7 % of standard deviation. 
The Fe3O4, and conventional Mn0.5Zn0.5Fe2O4 have a mean particle size 6.8 nm, and 




Figure 7-2 TEM images of uncoated engineered Mn0.5Zn0.5Fe2O4 nanoparticles 
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clearly confirmed that the EMZF nanoparticles have a narrow size distribution and a 
round shape and are well segregated. 
 In order to confirm the superparamagnetic nature, which is inevitably required for 
injection and successful cell differentiation in biomedicine applications, the magnetic 
properties of EMZF nanoparticles were explored by employing both ZFC/FC and 
minor hysteresis loop measurements (Figs. 7-3 (a) and (b)). As can be seen in Fig. 7-3 
(a), it was found that the EMZF nanoparticles had a mean blocking temperature 
 
 
Figure 7-3 (a) Measured ZFC/FC of EMZF-SPNPs at the applied field of 100 Oe, 
and (b) minor hysteresis loops of uncoated EMZF, conventional Mn0.5Zn0.5Fe2O4, and 
Fe3O4 SPNPs measured at the applied field of ± 140 Oe 
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(TB,mean) of 80 K and a maximum blocking temperature (TB,max) of 220 K indicating 
that they have superparamagnetic behavior at room temperature. In addition, the DC 
minor hysteresis loops measured at the Happl of ± 140 Oe (at room temperature) 
clearly verified that the EMZF and other nanoparticles did not show any magnetic 
hysteresis loss (Fig. 7-3 (b)). In particular, the EMZF SPNPs showed a higher 
magnetization than that of the Mn0.5Zn0.5Fe2O4 and Fe3O4 SPNPs. This result implies 
that the EMZF SPNPs are magnetically softer, in other words, have a lower magnetic 
anisotropy (a larger exchange energy or a higher magnetic susceptibility, χm) than that 
of the Mn0.5Zn0.5Fe2O4 and Fe3O4 SPNPs. Considering that the preferential site of 
Mn
2+
 cations is the A site of conventional Mn0.5Zn0.5Fe2O4 ferrite nanoparticles, the 
improved DC magnetic softness (or higher magnetization) of EMZF SPNPs is 
physically thought to be due to the possible substitution of Fe
2+
 cations with a 4 μB 
 
 
Figure 7-4 AC magnetically-induced heating temperature of the SPNPs measured in 
solid state 
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(Bohr magneton) in the B sites by Mn
2+
 cations with a 5 μB caused by the thermally 
controlled chemical potential during the modified HTTD synthesis process. 
 Figure 7-4 shows the TAC,mag characteristics of all the solid state SPNPs measured 
at the fixed Happl of 140 Oe and fappl of 110 kHz. Among the SPNPs, the EMZF SPNP 
showed the highest TAC,mag of 73.6 ℃ with the fastest heat up time. Moreover, it 
showed stable and well saturated heating temperature characteristics. The main 
physical mechanism of AC magnetically-induced heating of solid state soft ferrite 
SPNPs is understood that the “Néel relaxation loss power (PNeel relaxation loss)”, which is 
 
 
Figure 7-5 Intrinsic magnetic properties of EMZF, Mn0.5Zn0.5Fe2O4, and Fe3O4 SPNPs: 
(a) AC hysteresis loop and (b) out-of-phase magnetic susceptibility 
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directly proportional to the χ˝m and A (see Eqs. (5-2-1), (5-2-2), and (5-2-7)). In view 
of this physical mechanisms, the highest TAC,mag of the EMZF SPNPs can be clearly 
understood to directly result from the largest A and the highest χ˝m value as confirmed 
in Figs. 7-5 (a) and (d). The change in magnetic exchange energy (interaction) in the 
A and B sites of a conventional Mn0.5Zn0.5Fe2O4 SPNPs as well as the AC magnetic 
response (softness) due to the artificially controlled Mn
2+
 cation concentration and 
distribution during the chemical synthesis are mainly thought to be responsible for the 
significant improvement of the χ˝m value and the A  [3]. 
 
7.2.2 Coating status and AC heating characteristics of PEG coated SPNPs 
dispersed in fluids 
 It is well known that the coating and dispersion status of SPNPs in fluids affect 
the magnetic properties, the AC magnetically-induced heating characteristics, and the 
biocompatibility such as cell viability and cellular uptake [4,5]. Therefore, the PEG 
coating status of all the SPNPs@PEG was investigated to evaluate the feasibility to an 
intercellular hyperthermia agent for HSPs induction in RGCs. Figure 7-6 (a) shows 
the TEM images of EMZF@PEG SPNPs. It clearly illustrated that the EMZF@PEG 
SPNPs were well segregated and uniformly coated with around 2 nm thick PEG 
polymer layer. In addition, based on Fig. 7-6 (a), we speculate that other two 
SPNPs@PEG coated at the same conditions would have the similar coating status. 
The PEG coating layer on the surface of the SPNPs was also characterized using a 
FTIR spectrometer. The FTIR spectra of EMZF@PEG SPNPs are shown in Fig. 7-6 
(b). The C-O-C stretch band at 1103 cm
-1
 and -CH2 stretching vibrations at 955-965 
cm
-1
 were appeared, and the broad peak of hydroxyl groups were clearly observed in 
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the range of 3400-3550 cm
-1
. These peaks demonstrate that the surface of EMZF 
SPNPs was successfully modified by PEG layer. The dH, the PDI, and the Z-potential 
of all the SPNPs@PEG dispersed in D.I. water are shown in Figs. 7-7 (a) 
EMZF@PEG, (b) conventional Mn0.5Zn0.5Fe2O4@PEG, and (f) Fe3O4@PEG. All the 
ferrofluidic solutions similarly had a small mean dH of 21 nm ~ 23 nm with a narrow 
size distribution of ~ 10.56 % and a low PDI value in the range of 0.279 ~ 0.285 
indicating that they were uniformly and singly coated with PEG and the SPNPs@PEG 
were well dispersed in the fluids with minimal aggregation. 
 The AC magnetically-induced heating characteristics (TAC,mag and SLP) was 
 
 
Figure 7-6 (a) HR-TEM image of EMZF@PEG SPNPs dispersed in water (the 
EMZF SPNP successfully coated with a very thin PEG layer around 2 nm thickness 
and they were well dispersed in water with minimal aggregation) and (b) FTIR 
spectra of EMZF@PEG SPNPs disperse in water 
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investigated and compared to study the heating ability as an intercellular MFH agent 
for local induction of HSPs. Figure 7-8 shows the TAC,mag of (a) EMZF@PEG, (b) 
conventional Mn0.5Zn0.5Fe2O4@PEG, and (c) Fe3O4@PEG SPNPs as well as 
experimentally determined SLP values (Fig. 7-9). The concentration of SPNPs@PEG 
ferrofluids for AC heating measurement was varied from 5 mg/mL to 1 mg/mL. As 
can be seen in Figs. 7-8 (a) ~ (c), the EMZF@PEG ferrofluid showed the highest 
ΔTAC,mag of 8.62 ℃ at the concentration of 5 mg/mL (Mn0.5Zn0.5Fe2O4@PEG: 
4.1 ℃ and Fe3O4@PEG: 3.3 ℃ at 5 mg/mL) at the fixed AC magnetic field of fappl 
= 140 kHz, and Happl = 140 Oe and correspondingly the highest SLP value of 2021 
W/g (Mn0.5Zn0.5Fe2O4@PEG: 755.2 W/g and Fe3O4@PEG: 656.6 W/g, Fig. 7-9). The 
 
 
Figure 7-7 DLS data including hydrodynamic diameter (dH), poly dispersity Index 
(PDI) and Z-potential for three ferrofluids: (a) EMZF@PEG ferrofluid, (b) 
conventional Mn0.5Zn0.5Fe2O4@PEG ferrofluid, and (c) Fe3O4@PEG ferrofluid 
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exceptionally high SLP value of EMZF@PEG ferrofluid, which has not been ever 
reported before in MnxZn1-xFe2O4 SPNPs [6], is thought to be not only due to the 
improved AC heating ability in solid state resulted from the thermally modified Mn
2+
 
cation distributions or contributions in the A and B sites of conventional 
Mn0.5Zn0.5Fe2O4 ferrite nanoparticles but also due to the superior PEG coating status 
enabling to allow for both a smaller dH and a higher mono-dispersity resulted from 
extremely well controlled thin coating layer thickness. However, considering the 
results shown in Figs. 7-7 (a) ~ (c), the former would be more dominant for obtaining 
the extremely high SLP of EMZF@PEG ferrofluid. The AC magnetically-induced 
 
 
Figure 7-8 AC magnetically-induced heating temperature rise characteristics of three 
coated SPNPs dispersed in water measured at the fixed AC magnetic field of fappl = 140 
kHz and Happl = 140 Oe with varied concentration of 1 mg/mL ~ 5 mg/mL. (a) 
EMZF@PEG ferrofluid, (b) conventional Mn0.5Zn0.5Fe2O4@PEG ferrofluid, and (c) 
Fe3O4@PEG ferrofluid 
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heating power of ferrofluidic solutions with coated SPNPs is generally determined 
from the contributions of the "Néel relaxation loss power" due to the relaxation time, 
τN =τ0expKuV/kBT (τ0: relaxation time constant, Ku: anisotropy constant, V: volume of 
particles, kB: Boltzmann constant, and T: temperature), and the "Brown relaxation loss 
power" due to the relaxation time, τB = 4πη(dH/2)
3
/kBT (η: viscosity of fluidic solution)  
[7]. From this viewpoint, a higher dH along with a higher PDI caused by the severely 
aggregated coated SPNPs makes the τN and the τB longer due to the increase of V and 
the induction of undesirable magnetic dipole-dipole interactions in ferrofluids directly 
resulting in the severe reduction of SLP and ΔTAC,mag [5,9]. The extremely high SLP 
obtained from EMZF@PEG ferrofluid shown in Fig. 7-9 makes us apply it for a 
promising MFH agent to achieve high efficient local induction of HSPs, because the 
high enough SLP value can allow us to vary a wide range of "AC heating stress" 
 
 
Figure 7-9 The specific loss power (SLP) of all the ferrofluids calculated based on the 
AC heating characteristics obtained in Fig. 7-8 
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7.3 Biocompatibility – Cytotoxicity and Cellular uptake 
 The biocompatibilities including cell viability (cytotoxicity) and cellular uptake 
of the coated (PEG and silica) and uncoated SPNPs were investigated and compared 
by employing a Cell Counting Kit-8 (CCK-8) assay and TEM analysis. To explore the 
cellular uptake behavior of EMZF@PEG with RGCs, the RGCs were incubated at a 
10 mL of DMEM containing EMZF@PEG ferrofluid with concentrations of 300, 500, 
and 700 μg/mL for 24 hours. The effective mass of EMZF@PEG SPNPs uptake in the 
RGCs was determined by as ICP-MS. 
 The in-vitro biocompatibilities of uncoated and silica coated EMZF SPNPs and 
uncoated Fe3O4 SPNPs with RGCs were investigated. Figure 7-10 (a) shows the cell 
viability of uncoated Fe3O4 and EMZF SPNPs and silica coated EMZF 
(EMZF@silica) SPNPs with different nanoparticle concentrations. The coating 
thickness (t) dependence on the cell survival rate was also analyzed. It was found that 
the uncoated EMZF SPNPs have a higher cell survival rate of 73 % (midcytotoxicity) 
~ 91 % (noncytotoxicity) with a 10 % of standard deviation depending on the 
nanoparticle concentration. In addition, the uncoated EMZF SPNPs showed the higher 
cell survival rate than Fe3O4 SPNPs, particularly the 2 nm thick EMZF@silica SPNPs 
obviously enhanced the cell survival rate up to 83 % even at the highest particle 
concentration of 10 μg/ml. The significantly improved cell survival rate of the 
EMZF@silica SPNPs can be thought to be due to their lower agglomeration, rounder 
shape and more chemically stable surface than the uncoated EMZF SPNPs. However, 
in contrast, it was observed that the EMZF SPNPs coated with a 7 nm thick silica 
show a lower cell survival rate than the uncoated EMZF SPNPs. This undesirable 
effect can be thought to be due to the mechanically-induced stress applied to the cells 
caused by the large size of EMZF nanoparticles due to the thicker silica coating layer. 
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The study on the degree of penetration of uncoated EMZF and EMZF@silica (t: 2 
nm) SPNPs into the cells and cytological change caused by the penetrated 
nanoparticles were performed by a TEM using RGCs. In order to induce localized 
HSPs in the RGCs, the nanoparticle agents have to be located inside the cells without 
side effects. As can be seen in Fig. 7-10 (b), both the uncoated EMZF and the 
EMZF@silica SPNPs were penetrated well into the cytoplasm of RGCs (arrows) 
without obvious cytological change such as cell deformation. However, it was found 
that the EMZF SPNPs do not penetrate into the nuclei of RGCs, thus presenting no 
nuclei fragmentation. The EMZF@silica SPNPs obviously showed less agglomeration 
than the uncoated EMZF SPNPs. The weakening of positively charged surface 
 
 
Figure 7-10. Studies of in-vitro biocompatibility of uncoated Fe3O4 and EMZF 
SPNPs and silica coated EMZF SPNPs with RGCs: (a) Cell survival rate of uncoated 
EMZF and Fe3O4 and silica coated (thickness: 2 nm ~ 7 nm) EMZF SPNPs with 
different nanoparticle concentrations, and (b) TEM study results of RGCs 
containing uncoated and silica coated (2 nm) EMZFSPNPs 
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polarity of uncoated EMZF SPNPs due to the silica coating layer is thought to be 
mainly responsible for the less agglomeration.. 
 Figure 7-11 (a) shows the cell viability of EMZF@PEG and Fe3O4@PEG SPNPs 
with RGCs quantitatively analyzed at the different concentrations varied from 0 to 30 
µg/mL. As can be seen in Fig. 7-11 (a), the EMZF@PEG SPNPs had a high cell 
survival rate of 78 ~ 92.7 %, which is slightly higher and comparable with the 
Fe3O4@PEG SPNPs whose biocompatibility as an in-vivo MRI agent has been 
approved by the FDA. In addition, the cytological studies qualitatively analyzed by 
 
 
Figure 7-11. Studies of in-vitro biocompatibility of EMZF@PEG and Fe3O4@PEG 
SPNPs with RGCs: (a) Cell survival rate of EMZF@PEG and Fe3O4@PEG SPNPs 
with different concentrations, and (b) TEM study results of RGCs treated by 
EMZF@PEG SPNPs 
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TEM shown in Fig. 7-11 (b) confirmed that the EMZF@PEG SPNPs are well 
absorbed in the RGCs and located in the cytoplasm with no obvious cytological side 
effects such as cell deformation, cell apoptosis, and, nucleus fragmentation. 
 For the effective intercellular MFH with ferrofluid agents for local induction of 
HSPs, the cellular uptake efficiency should be quantitatively evaluated to determine 
the optimized concentration of ferrofluid agents, which can minimize the healthy cell 
death rate and improve induction efficiency. Table 7-1 summarizes the comparison 
data quantitatively analyzed by ICP-MS. The RGCs treated and incubated by 
EMZF@PEG ferrofluids with different concentrations of 300, 500, and 700 µg/mL 
had the effective (real) uptake concentration of 351.697, 557.877, and 1230.37 pg/cell, 
respectively, which are the highly improved cellular uptake characteristics compared 
to the previous reports [4,9,10]. Considering the number of cells used for this 
experiment, 3 × 10
6
 cells/well, the calculated uptake rate of EMZF@PEG with RGCs 
lies somewhere in the between 35.2 and 52.5 % depending on the concentration. The 
higher water dispersity (solubility) enhanced by the extremely thinner PEG coating 
layer thickness, and the smaller dH value along with a lower PDI, of EMZF@PEG 
shown in Fig. 7-7 (a) are thought to be the main chemical and physical reasons for the 
Table 7-1. The effective concentration of EMZF@PEG SPNPs uptake in the RGCs 
quantitatively analyzed using an ICP-MS. The RGCs were treated and incubated by 
EMZF@PEG ferrofluids with different concentrations of 300, 500, and 700 µg/mL 
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7.4 Local Induction of HSPs 72 in RGCs by MFH 
7.4.1 Optimization of concentration of EMZF@PEG SPNPs and holding 
time of AC heating stress for induction of HSPs 72 
  After confirmed and compared the feasibility of EMZF@PEG ferrofluid to 
an intercellular MFH agent such as intrinsic & extrinsic magnetic properties, water 
dispersity (solubility), cell viability along with cellular uptake, and AC heating ability, 
we conducted MFH using EMZF@PEG SPNP ferrofluidic agents to identify the local 
induction of HSPs 72 and to evaluate the working efficacy for a HSPs 72 induction 
agent in RGCs. 
 First of all, in order to determine the effective concentration of EMZF@PEG 
SPNPs ferrofluid and MFH time (holding time of AC heating stress in RGCs), we 
conducted MFH with different concentrations of EMZF@PEG ferrofluid and varied 
the holding time of AC heating (AC heating stress), TAC,mag, of MFH. Figure 7-12 
shows the dependence of EMZF@PEG ferrofluid concentrations on the TAC,mag 
 
 
Figure 7-12. AC magnetically-induced heating temperature rise characteristics of 
RGCs treated by EMZF@PEG SPNPs measured at the fixed applied frequency of 
140 kHz and magnetic field of 140 Oe with the concentrations varied from 300 
ug/mL to 700 ug/mL 
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). The concentration of EMZF@PEG SPNPs for AC heat generation in 
RGCs was varied from 300 μg/mL to 700 μg/mL to determine the optimal 
concentration of the SPNP agents for the effective induction of HSPs 72 in RGCs. 
After turning on the power, the TAC,mag of all the RGCs treated by EMZF@PEG 
SPNPs were increased with different heating up rate depending on the concentration 
and stably saturated and constantly maintained by adjusting the intensity of Happl. 
Among three different concentrations, the RGCs treated by the EMZF@PEG SPNPs 
of 300 μg/mL showed very low heating up rate. This low heating up characteristic of 
SPNP agents could not be applied to flexibly control the AC heating stress in RGCs 
for improving HSPs induction efficiency. Figure 7-13 shows the images of staining 
 
 
Figure 7-13. The stained results of HSPs 72 induction (left), nucleus (middle), and 
HSPs 72 + nucleus (right) in the RGCs after MFH using EMZF@PEG SPNPs with 
the concentration varied from 300 μg/mL to 700 μg/mL 
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results of HSPs 72 induction and nucleus in the RGCs after MFH using EMZF@PEG 
SPNPs with the concentration varied from 300 μg/mL to 700 μg/mL. It was found that 
HSPs 72 were successfully induced in RGCs by MFH using EMZF@PEG SPNPs. 
The HSPs 72 were induced with similar induction rate (visible HSPs 72 numbers) at 
all the concentrations of EMZF@PEG SPNPs. However, the visible cell numbers 
were dramatically decreased at the RGCs treated by the EMZF@PEG SPNPs of 700 
μg/mL. This can be possibly thought to be due to the higher mechanically-induced 
stress caused by the large amount of nanoparticles. Based on the experimental results 
of the heating up rate and the cell death rate, a 500 μg/mL was decided to be the 




Figure 7-14. AC magnetically-induced heating temperatures of RGCs treated by the 
EMZF@PEG SPNPs (500 μg/mL) with different holding time of AC heating from 
600 sec to 1200 sec measured at the fixed applied frequency of 140 kHz and magnetic 
field of 140 Oe 
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 The dependence of HSPs 72 induction and cell death behaviors on the holding 
time of AC heating (AC heating stress) in RGCs was investigated to determine the 
optimal MFH time. As can be seen in Fig. 7-14, the holding time of the AC heating to 
induce HSPs 72 in RGCs was varied from 600 sec to 1200 sec at a typical HSPs 
induction temperature of 40.5 ℃ ± 0.5 ℃. The concentration of the EMZF@PEG 
SPNPs was a 500 μg/mL and fappl, and Happl were 140 kHz, and 140 Oe, respectively. 
Figure 7-15 shows the images of staining results of HSPs 72 and nucleus in RGCs 
after MFH controlled the holding time of AC heating ((a) 600 sec, (b) 900 sec, and (c) 
1200 sec). It was observed that the HSPs 72 induction behavior was dependent on the 
AC heat holding time. The HSPs 72 were induced with the smaller induction rate at 




Figure 7-15. The stained results of HSPs 72 induction (left), nucleus (middle), and 
HSPs 72 + nucleus (right) in the RGCs after MFH using EMZF@PEG SPNPs 
controlled the holding time of AC heating: (a) 600 sec, (b) 900 sec, and (c) 1200 sec  
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at the AC heat holding time of 900 sec and 1200 sec. There was no significant 
difference in the HSPs 72 induction rate between 900 sec and 1200 sec. However, the 
cell death rate was also increased by increasing the holding time of AC heating and 
the highest visible cell loss was observed at the AC heat holding time of 1200 sec. 
These results indicate that the longer AC heating stress could induce more HSPs 72 
but it also could produce excessive thermal damage (or stress) to cells. Therefore, the 
AC heat holding time of 900 sec which showed the higher HSPs 72 induction rate and 
lower cell death rate was decided to be the optimal holding time of AC heating during 
induction process of HSPs 72 by MFH. 
 The induction of HSPs 72 was clearly confirmed by immunochemistry (Western 
blot analysis). In Western blot analysis to identify the induction of HSPs72 by MFH 
using EMZF@PEG SPNPs, we identified very weak immunoreactivity for HSPs 72 in 
the control groups (Fig. 7-16 (a) RGCs only, (b) RGCs + AC magnetic field (fappl = 
140 kHz, Happl = 140 Oe for 900 sec) + no EMZF@PEG SPNPs, and (c) RGCs + 
EMZF@PEG SPNPs (500 μg/mL) + no AC magnetic field). In contrast, as shown in 
Fig. 7-16 (d), strong immunoreactivity for HSPs 72 was detected in experimental 
group (RGCs + EMZF@PEG SPNPs (500 μg/mL) + AC magnetic field (fappl = 140 
kHz, Happl = 140 Oe for 900 sec )). 
 
7.4.2 Induction of HSPs 72 by MFH with EMZF@PEG and Fe3O4@PEG 
SPNPs 
 After decided the optimal concentration of EMZF@PEG SPNPs and holding time 
of AC heating, the AC magnetically-induced heating ability of EMZF@PEG in RGCs 
for induction of HSPs 72 was compared with Fe3O4@PEG SPNPs. For this work, we 
incubated RGCs for 24 hours with a 500 μg/mL of the two SPNPs@PEG for cellular 
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uptake process. Figure 7-17 shows the AC magnetically-induced heating temperature 
rise behaviors of RGC pellets treated by EMZF@PEG and Fe3O4@PEG SPNPs 
measured at the fixed AC magnetic field of fappl = 140 kHz and Happl = 140 Oe. After 
turning on the power, the TAC,mag of RGCs treated by EMZF@PEG SPNPs was 
gradually increased up to a 40.5 ℃ ± 0.5 ℃within a 382 sec. And then, it was stably 
saturated at the temperature and constantly maintained by adjusting the intensity of 
Happl for 900 sec. In contrast, after turning on the power, the TAC,mag of RGCs treated 
by Fe3O4@PEG SPNPs was suddenly dropped from 37 ℃ (initial cell temperature) to 
near the ambient (indoor) temperature, 22 ℃ and then it was only slightly increased 
after 400 sec at the same AC magnetic field conditions. The sudden drop and the very 
small increase of AC heating temperature observed from the RGC pellet with 
Fe3O4@PEG SPNPs is primarily thought to be due to the lower SLP, which can be the 
reason for the physical fact that the heat dissipation from the RGCs pellet is much 
faster than the AC heat generation at the applied AC magnetic field (fappl = 140 kHz, 
and Happl = 140 Oe). Figure 7-17 (b) shows the images of staining results of HSPs 72 
induction in the RGCs pellets treated by EMZF@PEG and Fe3O4@PEG nanofluids 
 
 
Figure 7-16 Western blot finding of HSPs 72 and β-actin (loading control). (a) RGCs 
only, (b) RGCs + AC magnetic field (fappl = 140 kHz, Happl = 140 Oe for 900 sec) + no 
EMZF@PEG SPNPs, (c) RGCs + EMZF@PEG SPNPs (500 μg/mL) + no AC 
magnetic field, and (d) RGCs + EMZF@PEG SPNPs (500 μg/mL) + AC magnetic 
field (fappl = 140 kHz, Happl = 140 Oe for 900 sec ). The protein levels of HSPs 72 were 
assessed by Western blotting, which identified the induction of HSPs 72 definitely in 
(d) than other controls groups (a, b, and c) 
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after MFH for 900 sec. As can be clearly seen in Figure 7-17 (b), the HSPs 72 were 
not induced in the RGC treated by the Fe3O4@PEG SPNPs, but the HSPs 72 were 
successfully induced in the RGCs treated by the EMZF@PEG SPNPs. The 
 
 
Figure 7-17. (a) AC magnetically-induced heating temperature rise behaviors of 
RGCs pellets treated by 500 µg/mL of EMZF@PEG and Fe3O4@PEG SPNPs 
measured at the fixed AC magnetic field of fappl = 140 kHz and Happl = 140 Oe, and 
(b) the stained results of HSPs 72 induction in the RGCs after MFH for 900 sec (left: 
HSPs 72, right: HSPs 72 + nucleus) 
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experimental results shown in Figure 7-17 clearly illustrate that a ferrofluidic agent 
with a critical SLP as high as possible is essentially required to make success of MFH 
for local induction of HSPs 72, particularly for biologically and physiologically safe 
HSPs 72 induction, in RGCs for glaucoma. 
 
7.4.3 Improvement of induction efficiency of HSPs 72 – control of 
increasing rate of AC heating stress 
 After confirmed the identification of HSPs 72 induction in RGCs by MFH using 
EMZF@PEG agents, more systematic studies were conducted to explore the effects of 
controlling AC heating stress on the induction rate of HSPs 72 and the cell death rate 
as well as to find the optimal increasing rate of AC heating stress enabling to achieve 
high efficient local induction of HSPs 72 in RGCs. As shown in Figure 7-18, in order 
to control the AC heating stress during the MFH based HSPs induction process, the 
AC heating-up rate (ΔT/Δt) to a constant HSPs temperature of 40.5 ℃ ± 0.5 ℃ was 
systematically changed from 0.118 ℃/s to 0.038 ℃/s by controlling the Happl from 













the fixed fappl of 140 kHz. For this experimental work, the RGCs pellet treated by 
EMZF@PEG SPNPs but, no applied AC magnetic field, was used as a control group 
to investigate the effects of mechanically-induced stress on the induction of HSPs 72 
in RGCs (see Figure 7-18 (a)) for comparison. As can be clearly seen in Figure 7-18, 
the induction of HSPs 72 was identified in the experimental groups (AC magnetically 
heated RGC pallets with different AC heating-up rate, AC heating stress, see Figures 
7-18 (b) ~ (e)), but the induction of HSPs 72 was not observed in the image of control 
group indicating that the contribution of 
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mechanically-induced stress due to the absorbed EMZF@PEG SPNPs to the 
induction of HSPs 72 in RGCs is negligible. In particular, it was interestingly found 
that the induction efficiency of HSPs 72 and the healthy RGC cell death behavior (or 
cell death rate) have a strong dependence on the increasing rate of AC heating stress 
(or AC heating-up rate) electromagnetically controlled by the externally applied AC 
magnetic field. As apparently displayed in Figures 7-18 (b) ~ (e), the induction 
efficiency of HSPs 72 and the viable cell (nucleus) numbers were dramatically 
 
 
Figure 7-18. Dependence of increasing rate of AC heating stress or AC heating-up 
rate, (ΔT/Δt) to a constant HSPs temperature of 40.5 ℃ ± 0.5 ℃ on the local 
induction rate of HSPs 72 and the cell survival rate (or cell death rate) in RGCs 
treated by 500 µg/mL of EMZF@PEG ferrofluidic solution.: (a) control group, 
RGCs with EMZF@PEG SPNPs but no applied AC magnetic field, (b) ΔT/Δt = 
0.118 ℃/s, fappl= 140 kHz, Happl = 160 Oe, (c) ΔT/Δt = 0.091 ℃/s, fappl= 140 kHz, Happl 
= 140 Oe, (d) ΔT/Δt = 0.062 ℃/s, fappl= 140 kHz, Happl = 130 Oe, and (e) ΔT/Δt = 
0.038 ℃/s, fappl= 140 kHz, Happl = 120 Oe 
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increased by decreasing the AC heating-up rate (or the increasing rate of AC heating 
stress). A relative numerical calculation method for both HSPs 72 induction rate 
(visible number of HSPs 72 / visible number of nucleus × 100 (%)) and cell (nucleus) 
survival rate (visible nucleus number after MFH / visible nucleus number in the 
control group × 100 (%)) was employed and modified for further numerical analysis 
[14]. According to the calculation results, the RGCs pellet heated with the slowest AC 
heating-up rate of 0.038 ℃/s exhibited significantly improved HSPs 72 induction rate 
of 71.11 % and the cell survival rate of 70.27 %, while, the RGCs pellet heated with 
the fastest AC heating-up rate of 0.118 ℃/s exhibited the lowest HSPs 72 induction 
rate of 25.64 % and the cell survival rate of 47.29 %. The apparently confirmed 
dependence of AC heating stress on the both induction efficiency of HSPs 72 and cell 
survival rate as well as the significantly improved HSPs 72 induction efficiency can 
be elucidated and understood by considering the physiological/biological correlation 
between the induction process of HSPs 72 and the response behavior of RGCs to the 
time controlled thermal stress: 1) the rapid increase of AC heating stress inhibits the 
RGCs treated by EMZF@PEG SPNPs from possessing enough time to form a 
thermally steady state with ambient temperature, thus the RGCs cannot retain enough 
thermal energy to produce stress for improving the induction rate of HSPs 72, and 2) 
the sudden change of stress in the RGCs caused by the faster increasing rate of AC 
heating stress gives rise to non-equilibrium state between the net growth rate and the 
net death rate in the RGCs leading to the acceleration of cell damage and the 
correspondingly higher cell death rate during the induction of HSPs process [15]. 
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7.4.4 Improvement of induction efficiency of HSPs 72 – control of duty 
cycle of AC heating stress 
 In this work, we changed a duty cycle of the AC heating stress (AC heating or AC 
hating temperature) in RGCs to explore the effects of controlling the heat duration 
 
 
Figure 7-20. Duty cycle controlled AC heating temperatures (AC heating) of RGCs 




Figure 7-19. A schematic diagram to illustrate a duty cycle of the AC heating stress 
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time (τH, holding time of AC heating stress) and the recovery time (τR) from the AC 
heating stress on the HSPs 72 induction and cell death rate as well as to find the 
optimal ratio of the τH to the τR to achieve the high efficient local induction of HSPs 
72 in RGCs. The duty cycle, D, of AC heating stress was defined as the ratio of the τH 
to the heat repetition interval (HRI = τH + τR), as shown in Fig. 7-19. 
 Figure 7-20 shows the duty cycle controlled AC heating temperaturs ((a) D: 25 %, 
(b) D: 50 %, (c) D: 75 %, and (d) D: 100 %) of RGCs treated by EMZF@PEG SPNPs 
ferrofluidic solution (500 μg/mL). The duty cycle of the AC heating was 
systematically changed at a typical HSPs temperature of 40.5 ℃ ± 0.5 ℃ (on mode) 
by controlling the Happl (on mode, τH: ~ 170 Oe and off mode, τR: 100 Oe ~ 110 Oe (~ 






). The HRI time 
in one cycle of the AC heating was 600 sec and the τR were 450 sec (D: 25 %, τH: 150 
sec), 300 sec (D: 50 %, τH: 300 sec), and 150 sec (D: 75 %, τH: 450 sec) in the HRI. 
 After conducted the MFH controlled the duty cycle of the AC heating in RGCs, 
the dependence of HSPs 72 induction and the cell death rate on the controlling duty 
cycle of the AC heaing was investigated using the images of stained RGCs. Figure 
7-21 shows the images of staining results of HSPs 72 induction (left) and nucleus  
(right) in the RGCs treated by 500 μg/mL of EMZF@PEG SPNPs. The images clearly 
showed that the HSPs 72 induction rate (visible number of HSPs 72) was gradually 
increaed by increasing the duty cycle of the AC heating. However, it was also 
observed that the cell survival rate (visible number of cells (nucleus)) was rapidly 
decreased by increasing the duty cycle. 
 A relative numerical calculation method for both HSPs 72 induction rate (RH) and 
cell death rate (RC) was employed for numerical analysis [14]. In addition, in order to 
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analyze the effect of the controlling duty cycle of the AC heating on the efficiency of 







 .                                                (7-4-1) 
 
Figure 7-22 (a) shows the calculation results of the RH and the RC in RGCs after MFH 
controlled the duty cycle (duty factor) of the AC heating. According to the calculation 
results, the 25 % duty cycle (duty factor: 0.25) exhibited the lowest RH of 10.26 % 
 
 
Figure 7-21. The dependence of HSPs 72 induction and the cell death rate on the 
controlling duty cycle of the AC heaing.: (a) D: 25 %, (b) D: 50 %, (c) D: 75 %, and 
(d) D: 100 % 
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and the RC of 22.1 %, while, the 100 % duty cycle (duty factor: 1) exhibited the 
highest RH of 26.92 % and the RC of 65.4 %. In other words, the RH was slightly 
improved by increasing the τH, while the RC was dramatically increased by increasing 
the τH (or decreasing the τR). This result indicates that the HSPs 72 induction and cell 
death behaviors in RGCs during MFH were dependent on the controlling duty cycle 
(or τH and τR). This observation allows us to speculate that the cell death is more 
sensitive to the AC heating stress than the HSPs 72 induction. Therefore, based on the 
our observation, the optimized τR of RGCs from the AC heating stress during HSPs 72 
 
 
Figure 7-22. The calculation results of (a) cell death rate and HSPs 72 induction rate 
and (b) HSPs 72 induction efficiency by employing the Kobayashi’s methods [14] 
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induction process could be considered for minimizing the cell death for the high η. 
The η depending on the duty cycle (or the ratio of the τR to the τH) were determined 
using Eq. (7-4-1), as shown in Fig. 7-22 (b). In this work, the optimal ratio of the τR to 
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7.5 A new infusion technique to introduce SPNP agents to the retina 
layer 
 Based on the verified high cell viability and efficacy of EMZF SPNPs for 
induction of HSPs 72 (in-vitro), the biocompatibility of uncoated and coated EMZF 
SPNPs in an in-vivo environment such as infusion of the SPNPs to the surface of 
retina, tissue deformation including inflammation, and cell apoptosis caused by the 
injected nanoparticles were further investigated to evaluate their biotechnical 
feasibility for real clinical localized HSPs agent applications. For a successful 
infusion of the SPNPs, a new infusion technique based on diffusion method that is 
widely being used to medicate the eye in clinics was employed to introduce the 
nanoparticles to the eye. Due to the specific technical and biological limitation when 
SPNPs were intravenously injected through the choroid in an eyeball, we decided to 
attempt to directly inject the EMZF SPNPs through the vitreous body and diffuse 
them to the surface of the retina (Fig. 23 (a) and (b)). This study is understood as the 
first attempt to utilize the diffusion technique to infuse the SPNP agents into the 
surface of retina (RGCs). Figures 23 (c) ~ (f) show the histological exam results of the 
retina paraffin blocks ((c) control, (d) exposed to the uncoated EMZF SPNPs, and (e) 
and (f) exposed to the EMZF SPNPs@silica). As can be seen in Fig. 23 (d) and (e), 
the injected nanoparticles were successfully diffused into the retina, more specifically 
most of the nanoparticles were found in the inner plexiform layer. The inner plexiform 
layer is the most adjacent layer to RGCs, therefore highly effective heat transfer from 
the injected nanoparticles to the RGCs can be expected. In addition, the nanoparticles 
diffused into the retina showed a high biocompatibility. The retina exposed to both the 
uncoated and the silica coated EMZF SPNPs did not show any tissue deformation and 
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inflammation for two weeks. However, the uncoated and silica coated EMZF SPNPs 
 
 
Figure 7-23. A new infusion technique to introduce SPNPs to the surface of retina 
layer and the histological exam results to investigate the distribution status of the 
injected SPNPs and cell apoptosis: (a) Injection of uncoated and silica coated EMZF 
SPNPs into the rat eyeball and (b) Diffusion of the EMZF SPNPs thorough the 
vitreous body, (c) Control retina paraffin block, (d) Histological exam results of the 
retina paraffin block exposed to the uncoated EMZF SPNPs and (e) The EMZF 
SPNPs@silica, and (f) The enlarged inner plexiform layer of the retina paraffin 
block containing the EMZF SPNPs@silica 
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showed completely different diffusion (injection) behavior in the retina. As can be 
seen in Fig. 23 (d), the largely aggregated uncoated EMZF SPNPs were observed in 
the inner plexiform layer (arrows), while, the EMZF SPNPs@silica only showed a 
few small agglomerations (Fig. 23-(e)), moreover they were uniformly distributed in 
the inner plexiform layer (black dots in Fig. 23 (f)). The diffused nanoparticles should 
be uniformly distributed in the retina, particularly RGC layer or its adjacent layer such 
as inner plexiform layer, without large agglomeration in order to apply uniform 
TAC,mag to the RGCs as well as to minimize cell stress. The largely aggregated 
nanoparticles can lead to stress in the cells, which decrease the cell viability, moreover, 
they might generate an undesirably higher TAC,mag than expected in the vicinity, which 
can damage the healthy cells. The successful injection of the EMZF SPNP@silica 
agent into the retina demonstrated by a new infusion technique more strongly support 
the biotechnical potential of MFH to induce local HSPs 72 for “ocular 
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7.6 Summary 
 Firstly, it was experimentally confirmed that the EMZF SPNPs with a 5.5 nm 
mean particle size, particularly thin biocompatible materials (PEG and silica) coated 
EMZF SPNPs, showed promising magnetic, structural, biological, and AC 
magnetically-induced heating characteristics inevitably requiring for a MFH agent to 
induce HSPs 72 in RGCs. 
 Secondly, the HSPs 72 were successfully induced in RGCs by AC heating stress 
controllable MFH. It was demonstrated that the slower increasing rate of AC heating 
stress controlled by the externally applied AC magnetic field in the biologically and 
physiologically safe range is crucial factor to significantly improve the induction of 
HSPs 72 and effectively reduce the cell death rate of RGCs during the MFH. It was 
also found that the HSPs 72 induction rate was gradually increased by increasing the 
duty cycle of the AC heating stress but the cell survival rate was rapidly decreased by 
increasing the duty cycle. The experimentally analyzed results of the η showed that 
the optimal ratio of the τR to the τH (or duty cycle) can improve the efficiency of HSPs 
72 induction by minimizing the cell death during HSPs 72 induction process. 
 Lastly, the successful demonstration of a newly designed infusion technique using 
a rat animal pilot study, which diffuses the coated EMZF SPNPs through the vitreous 
body to the retina, more strongly verified that the MFH based HSPs 72 induction 
using coated EMZF SPNPs can be feasible for “ocular neuroprotection” modality in 
glaucoma clinics. All the experimental results shown in this study strongly suggest 
that the “ocular neuroprotection” based on the HSPs 72 induction by AC heating 
stress controllable MFH can be an innovative biotechnical approach for efficacious 
treatment modality in modern glaucoma clinics. 
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1. Conclusions 
 In recent years, the interest in glaucoma treatment has shifted toward ocular 
neuroprotection induced by heat shock proteins (HSPs) 72. However, the current 
biotechnical approaches to induced HSPs 72 have critical limits to use in modern 
clinics due to undesirable systemic or chemical side effects and correspondingly low 
local induction efficiency of HSPs 72. Therefore, to settle down these current 
biotechnical challenges, the development of new biotechnical or biomedical 
engineering approach enabling to achieve high efficient local induction of HSPs 72 in 
RGCs is inevitably required for ocular neuroprotection in modern glaucoma clinics. 
 The aim of this work was to develop the AC heating stress controllable MFH 
using a high performance SPNP agent as a new-biotechnical approach to effectively 
control the local induction of HSPs 72 and to minimize the death rate of healthy cells 
during the induction of HSPs 72 in RGCs. The main results of this work are 
summarized below, followed by suggestions for future work 
 
A. It was clearly demonstrated that the Fe3O4 nanoparticles with different mean 
diameters systematically controlled from 4.2 to 22.5 nm have three different 
magnetic phases (pure ferrimagnetic phase, mixed phase, and pure 
superparamagnetic phase) and correspondingly different SLP characteristics 
depending on the particle sizes. The pure SP-Fe3O4 nanoparticles (d < 9.8 nm) 
showed a very low SLP (< 45 W/g) because of the naturally small AAC (or χ") 
value and accordingly low PNéel relaxation loss which only contributes to the Ptotal. This 
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would be considered as the most challengeable physical limit for the application of 
pure SP-Fe3O4 nanoparticles to a MFH agent.  
 
B. In order to develop a new powerful SPNP for MFH agent applications, the 
physical mechanisms and physical parameters of the AC magnetically-induced 
heating of SPNPs were investigated. Solid state MFe2O4 (M = Mg, Ni, and 
Mn0.5Zn0.5) SPNPs were used to explore the physical mechanisms of AC 
magnetically-induced heating and identify what physical parameters would be the 
most critical to enhance the AC heating power of SPNPs. It was demonstrated that 
the PNeel relaxation loss (or PAC hysteresis loss) dominantly contributed to the Ptotal of SPNPs. 
Moreover, it was physically demonstrated that the A (or χ˝m), directly relevant to 
the AC magnetic softness, are the most crucial physical parameters to enhance the 
PNeel relaxation loss. Controlling the magnetic anisotropy, the exchange coupling 
(energy), and the relaxation time constant of SPNPs by tailoring the magnetic and 
structural properties of SPNPs would be the most efficient technical approaches to 
significantly improve the physical parameters for their MFH agent applications. 
 
C. It was empirically found that the PBrown relaxation loss was severely affected by the 
surrounding environment (viscosity) and its contribution to the Ptotal and the SLP 
was drastically decreased with increasing the viscosity up to cytoplasm level. 
Whereas, the contribution of PNéel relaxation loss to the Ptotal and the SLP was 
independent to the variation of surrounding environment (viscosity) of ferrofluids. 
These experimentally and physically analyzed results strongly support the physical 
fact that the effectiveness of MFH can be optimized by enhancing the PNéel relaxation 
loss rather than the PBrown relaxation loss of SPNP agents in ferrofluids. 
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D. The ΔTAC,mag and the magnetic properties of uncoated solid state 
MnxZn1-xFe2O4 SPNPs had a strong dependence on the Mn
2+
 cation concentration. 
Among the MnxZn1-xFe2O4 SPNPs, the Mn0.5Zn0.5Fe2O4 SPNP showed the highest 
ΔTAC,mag, and biocompatibility. It was demonstrated that the higher χ˝m (and largest 
A) value directly relevant to the Néel relaxation (or AC magnetic softness) and the 
higher chemical stability systematically controlled by the replacement of Mn
2+
 
cations by the Zn
2+
 cations on the tetrahedral site are the primary physical reason 
for the biotechnical promises of the Mn0.5Zn0.5Fe2O4 SPNP. 
 
E. It was experimentally confirmed that the EMZF SPNP coated with thin 
biocompatible materials (PEG and silica) showed promising magnetic, structural, 
biological, and AC magnetically-induced heating characteristics (TAC,mag: 73.6 ℃ 
and SLP: 2021 W/g) inevitably requiring for a MFH agent. These results strongly 
demonstrated the coated EMZF SPNP can be a powerful MFH agent to 
successfully control the AC heating stress in RGCs for high efficient local 
induction of HSPs 72. 
 
F. HSPs 72 were successfully induced in RGCs by AC heating stress controllable 
MFH. It was demonstrated that the slower increasing rate of AC heating stress 
controlled by the externally applied AC magnetic field in the biologically and 






) is crucial factor to 
significantly improve the induction of HSPs 72 and effectively reduce the cell 
death rate of RGCs during the MFH. 
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G. It was observed that the HSPs 72 induction rate was gradually increased by 
increasing the duty cycle of the AC heating stress. However, the cell survival rate 
was rapidly decreased by increasing the duty cycle of the AC heating stress. The 
analyzed results of the η (HSPs 72 induction efficiency) showed that the optimal 
ratio of the τR to the τH (or duty cycle) can improve the efficiency of HSPs 72 
induction by minimizing the cell death during HSPs 72 induction process. 
 
H. The successful demonstration of a newly designed infusion technique using a rat 
animal pilot study, which diffuses the coated EMZF SPNPs through the vitreous 
body to the retina, more strongly verified that the MFH based HSPs 72 induction 
using coated EMZF SPNPs can be feasible for “ocular neuroprotection” modality 
in glaucoma clinics. 
 
 We expect that these findings will shed new light on modern glaucoma clinics 
that AC heating stress controllable MFH using a high performance SPNP ferrofluidic 
agent can be a powerful nano-biotechnical approach leading to a successful 
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8.2 Suggestions for Future Work 
 The following research ideas are possible future projects that a direct continuation 
of the work conducted in this thesis. 
- In this study, we successfully injected the SPNP agents into the retina through 
the vitreous body of a rat eye by the newly designed infusion technique. 
However, the infusion efficiency and diffusion time of the SPNPs need to be 
improved for further animal study. One of the possible methods for improving 
the infusion efficiency and time is to apply the magnetic field. Under the 
action of the magnetic field gradient the SPNPs move to the target site. 
- The concentration of infused SPNPs was small for generating the sufficient 
AC heating in the rat eye because the volume of rat eyes is too small to inject 
the enough concentration of SPNPs . Therefore, in order to inject the larger 
amount of SPNPs, a larger eye such as rabbit’s eyes should be considered. 
 Furthermore, the demonstration of high efficient induction of HSPs 72 by AC 
heating stress controllable MFH provides us another clinically crucial information that 
this nano-biotechnical modality can be further extended to the protection of damaged 
neurons in CNS for treating other neurodegenerative diseases (such as Alzheimer’s 
disease, Parkinson’s disease, dementia, and stroke). 
 
 
 
 
 
 
 
